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Abstract 
Immune mediated mechanisms are thought to contribute to recurrent 
pregnancy losses. A number of treatment options with limited evidence are 
being used in clinical practice to treat women with recurrent miscarriages.  
 
The objectives of this thesis was  
a. To summarise the available evidence for granulocyte colony stimulating 
factor (G-CSF) in reproductive medicine. 
b. To perform a randomised controlled study (RCT) to evaluate the efficacy 
and safety of recombinant human granulocyte colony stimulating factor 
(rhG-CSF) in women with unexplained recurrent miscarriages.  
 
The main conclusions from this thesis are:   
a. The systematic narrative review found that available evidence is of poor 
quality, but suggestive of benefit with granulocyte colony stimulating 
factor in women with recurrent miscarriages.   
b. The RCT concluded that administration of rhG-CSF does not improve 
pregnancy outcomes among women with a history of unexplained 
recurrent miscarriages. RhG-CSF appears to be safe for both mothers and 
their offspring/s. 
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CHAPTER 1 
RECURRENT MISCARRIAGE - BACKGROUND AND UNCERTAINTIES 
 
Introduction 
Loss of pregnancy prior to viability is defined as a miscarriage. Approximately 
1 in 5 pregnancies sadly end in these sporadic events, the risks of which 
increases with advancing maternal age. The most common reason for 
miscarriage is chromosomal abnormality in the embryo.  Repeated episodes of 
sporadic miscarriages result in recurrent miscarriages (RM). Many terms have 
been used in the past to describe repeated miscarriages such as repeated 
abortions, repeated pregnancy failure and repeated embryo demise. Women 
prefer clinicians to use more sensitive terminologies as some of the above terms 
may otherwise imply blame1.   
 
Royal College of Obstetricians and Gynaecologists (RCOG) define recurrent 
miscarriage as 3 or more pregnancy loss prior to 24 weeks of gestation2. RM 
affects 1% of couples. The prevalence increases to 3% if biochemical pregnancies 
were added and accounted for3.  There is considerable debate regarding the 
definition, incidence and management of recurrent miscarriages. American 
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Society for Reproductive Medicine (ASRM) defines recurrent miscarriage as 2 
or more documented pregnancy loss prior to 20 weeks of gestation4. These are 
pregnancies either confirmed by ultrasonography or by histology. Based on this 
definition the incidence ranges from 3-5%. Jaslow et al suggested that outcomes 
of index pregnancy following 2 or 3 miscarriages were similar5 and therefore, a 
clinical plea to revisit the true definition of RM and to initiate investigations 
after 2 miscarriages.  
Even though the terms recurrent pregnancy loss and recurrent miscarriage 
were used interchangeably, recent studies suggest they represent two different 
entities6.  
 
Recurrent pregnancy loss entails loss of any type of pregnancy irrespective of 
its location and gestational age (including molar, ectopic or biochemical) and 
RM is exclusively used for pregnancy failure following a clinically confirmed 
pregnancy i.e. a visualised pregnancy. Biochemical pregnancies are also termed 
as non-visualised pregnancies. Clinical miscarriages may be classified as early 
(less than 12 weeks of gestation and late clinical pregnancy losses (over 12 
weeks of gestation). RM can be consecutive or non-consecutive. 
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Furthermore, based on previous livebirth/s, RM can be classified into:  
a. Primary – is loss of 3 or pregnancies without any livebirth 
b. Secondary – is loss of 3 or more pregnancies following a livebirth or  
c. Tertiary – is loss of 3 or more pregnancies; however, in no particular 
order with livebirth/s in between. 
 
It is imperative to distinguish these conditions to offer reliable and accurate 
opinion to counsel women regarding the long-term prognosis. 
 
Impact of RM 
RM can result in significant emotional, physical and financial implications for a 
couple. About a third of couples experience depression and anxiety while 
suffering RM7. This may result in a strain in their relationship. Most of the 
studies linked recurrent miscarriages with only the female partners8,9.  The 
female partner may have emotional disturbances after the episode which may 
last for days or months. It is also quite normal to feel anxious about the 
following pregnancy and its outcome. Recent studies suggested that male 
partners also undergo same emotional trauma as their female partners7.  
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Established RM clinics should have facilities to organise behavioural therapy, 
counselling support and also support groups for couple with RM. 
Clinical Evaluation  
RM is a multifactorial condition and in spite of comprehensive investigation 
pathway followed by clinicians, only about 50% of RM are attributed to an 
identifiable cause. The remaining cases are considered to be unexplained.  
 
Importance of a detailed history 
Epidemiological and life style factors can play a role in recurrent miscarriage. 
Niekerk et al reported increasing risk of miscarriage with earlier gestation, 
majority of which occurs under 12 weeks of gestation10. Advancing maternal 
age which causes decline in oocyte number and quality also increases the risk of 
miscarriage. Previous pregnancy loss increases the risk of miscarriage in index 
pregnancy11.  Increase in paternal age was associated with autism in offspring 
until now, but new research suggests increase in miscarriage related to sperm 
DNA fragmentation and sperm aneuploidy. Consanguineous marriages can 
also increase the risk of RM by increased risk of malformations and autosomal 
recessive diseases. 
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Previous studies by Lashen et al and Lo et al suggested BMI as a negative 
prognostic factor for live birth in index pregnancy12,13; however, Kolte et al6 
suggested no statistically significant relation. Life style factors like high intake 
of caffeine, tobacco and alcohol and increased stress are associated with poor 
obstetric outcome and therefore may also have a link in early pregnancy.  
 
Hemminki et al in a questionnaire based study reported that risks of 
miscarriage varied by education and occupation14 . Contrary to belief, 
miscarriage rates were higher in the middle social class rather than lower social 
class. Arbitrarily, it was explained by increased occupational stress levels and 
higher age at first pregnancy.  In a more recent study by Catak et al, risk of 
spontaneous miscarriages were higher in women who had less than 5 years of 
education and also for mothers who were employed at the time of conception15 . 
Further, Norsker et al in a cohort study demonstrated that women with <10 
years of education had an elevated risk of spontaneous abortion when 
compared with women with >12 years of education (HR 1.19 (95% CI 1.05 to 
1.34))16 . 
Therefore, information should be gathered about social class, educational level, 
occupation and daily activity levels as part of assessment and pre-pregnancy 
counselling.   
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 The investigations can be performed on the: 
1. Female partner 
2. Male partner and/or the 
3. Embryo 
 
The clinical evaluation and strength of evidence for association with recurrent 
miscarriage are listed in table 1.1, table 1.2 and table 1.3.  
I have collated this evidence from basic sciences, randomised controlled studies, 
non-randomised controlled studies, clinical reviews, observational studies, case 
reports and clinical guidelines.  
I have classified the strength of evidence as strong, limited or unknown. 
Strong – Evidence from prospective randomised or non-randomised trials, 
which provide a clear and compelling effect on clinical outcomes. 
Limited – Evidence from uncontrolled studies and case reports which proved 
little or no enhancement in clinical outcomes. 
Unknown – Evidence which is currently hypothetical. 
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Table 1.1 – Clinical Evaluation for the female partner 
Risk Factors Strength of evidence 
for association with 
recurrent miscarriage 
Genetic  
 Parental karyotyping17 Strong 
  
Anatomic – Uterine abnormality  
 Uterine septum18 Limited 
 Sub mucous fibroids19 Limited 
 Sub mucous polyp20 Limited 
 Intrauterine adhesions21 Limited 
 Hydrosalpinx22 Limited 
 Cervical Insufficiency23 – 2nd trimester Strong 
  
Infections24  
 Chlamydia Limited 
 TORCH Limited 
 Endometritis Limited 
  
Endocrinological2  
 LPD Limited 
 Hypothyroidism/hyperthyroidism Limited 
 Glucose metabolism Limited 
 PRL Limited 
 FSH, LH, E2, AMH Limited 
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 PCOS profile Limited 
 Vit D Limited 
  
Immunological incl. autoimmune 25,26  
 LA Strong 
 Antiphospholipid ab Strong 
 Beta 2 glycoprotein Strong 
 Auto-antibodies Limited 
 Anti-nuclear antibodies Limited 
  
Thrombophilia26,27  
 Antithrombin 3 Limited 
 Factor V Leiden Limited 
 Factor 2 prothrombin Limited 
 MTHFR Limited 
 Protein C and Protein S Limited 
 PAI Polymorphism Limited 
 C4M2 Limited 
  
Extended reproductive immunology tests28,29,30  
 Functional NK cell profile Limited 
 TH1:TH2 Intracellular cytokine Ratio Limited 
 LAD testing Limited 
 HLA DQ – alpha  Limited 
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Table 1.2 - Clinical Evaluation for the male partner 
Risk Factors Strength of evidence 
for association with 
recurrent miscarriage 
Genetic  
Parental karyotyping17 Limited 
  
Inherited Thrombophilia26,27  
 C4M2   Limited 
 Factor V Leiden Limited 
  
Extended Reproductive immunology28,29,30  
 HLA DQ – alpha Limited 
 LAD Limited 
  
Sperm31,32  
 Sperm Aneuploidy Limited 
 DNA Fragmentation Limited 
  
Table 1.3 - Clinical Evaluation on the embryo 
Risk Factors Strength of evidence 
for association with 
recurrent miscarriage 
Genetic  
 Fetal Karyotyping33 Strong 
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Clinical Evaluation for Recurrent Miscarriage  
Genetic investigations 
The incidence of chromosomal abnormalities in one partner is 2.7 % to 6% for 
couple suffering RM34,35. Due to this relatively low incidence of translocations, 
routine testing in form of parental karyotyping is not recommended, for cost-
effective reasons. Parental karyotyping is mainly indicated if there is evidence 
of translocation after fetal karyotyping. However, this does not predict the risk 
of unbalanced translocation in the offspring36. 
Clinicians may also initiate parental karyotyping if there is history of multiple 
miscarriages, family history of RM or else a history of translocations in siblings 
of partners with RM.  The most common form of translocations is balanced 
translocation. Other abnormalities may be inversion, deletion or duplications of 
parental chromosomes37. 
 
Uterine abnormalities 
Disruption of normal development of female genital tract can result in uterine 
abnormalities. The prevalence of uterine abnormalities ranges between 1 to 10% 
in women with RM38. The abnormalities can be uterus with rudimentary horn, 
unicornuate, didelphis, septate or arcuate uterus. All uterine anomalies may 
result in adverse pregnancy outcomes.   
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Septate uterus is the most common significant uterine malformation18.  
Investigations performed are ultrasonography, hystero-salpingography, saline 
sonogram, hysteroscopy and/or laparoscopy. Latest studies suggests three 
dimensional ultrasound scan to diagnose uterine abnormalities has high 
sensitivity and specificity compared to hystero-laparoscopy39. 
 
Infections 
There is no indication for screening for infections during early pregnancy 
unless there is evidence of acute onset or systemic evidence of infections. 
Infections like chlamydia, genital tuberculosis may result in fallopian tube 
blockage or endometrial adhesions respectively and cause subfertility rather 
than recurrent miscarriages40. Plasma cell infiltrate in endometrium as a result 
of repeated subclinical infections may result in chronic endometritis41.  
 
Mcqueen et al 2015 and Cicinelli et al suggested that incidence of endometritis 
can be as high as 58% in women with recurrent miscarriage42,43. They also 
suggested that prophylactic antibiotics improved live birth rates in the index 
pregnancy. Due to lack of randomised controlled studies routine use of 
antibiotics are not recommended in women with recurrent miscarriages. 
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Endocrine 
Uncontrolled thyroid disorders, glucose metabolism and raised prolactin are 
related to subfertility, sporadic miscarriages and adverse obstetric outcomes2. 
The link between these conditions and recurrent miscarriage is weak. Therefore 
routine screening for thyroid abnormalities, HbA1C , prolactin or polycystic 
ovaries is not recommended. However, some clinicians perform these tests if 
patients present symptoms for the above aspects. As these investigations are 
considered to be relatively inexpensive tests, they form part of pre-pregnancy 
counselling in women with recurrent miscarriage. Defect in corpus luteum 
resulting in low progesterone levels in the mid luteal phase may result in a non-
receptive endometrium and can cause recurrent miscarriages44. Reproductive 
endocrinologists consider this disorder as luteal phase defect. There are 
inconsistencies regarding this as some groups rely on a histological diagnosis 
and therefore can pose practical diagnostic difficulties in routine clinical 
practise. A higher prevalence for anti-thyroid antibodies is identified in women 
with recurrent miscarriage. A meta-analysis suggested that presence of TPO 
antibodies increased risk of RM by an odds ratio with 2.345. However, routine 
testing is not advised outside research settings.  
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Thrombophilia 
Thrombophilic factors can be acquired or inherited. Acquired thrombophilia is 
a well-recognised risk factor for recurrent miscarriages. Presence of lupus 
anticoagulant, high titres of anti-cardiolipin antibodies and/or beta 2 
glycoprotein are associated with recurrent miscarriages2. 
It is postulated that thrombophilia factors can increase the risk of placental 
thrombosis. This results in reduced placental perfusion causing recurrent 
miscarriage26. Complement activation resulting in recruitment of inflammatory 
cells damages the fetus and placenta in acquired thrombophilia. Studies in mice 
suggest the pathway in inherited thrombophilia lack thrombomodulin protein 
C inhibiting placental trophoblast cells and thus impairing placental 
development27. There is conflicting evidence for the relationship between 
inherited thrombophilia and recurrent miscarriage. Some older studies are in 
favour of this relationship while more recent studies refute the evidence. Jivraj 
et al suggested increased risk of miscarriage in index pregnancy (after a 
diagnosis of recurrent miscarriage) if either the female or the male partner had 
evidence of inherited thrombophilia46. 
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Immunological investigations 
There is emerging evidence that some of the unexplained RM may be due to an 
abnormal maternal immune system. Recently, there is considerable interest in 
reproductive immunology testing, mainly the peripheral and uterine natural 
killer cell profile. 
Peripheral and uterine NK cells differ in structure and function and there are no 
universally accepted normal ranges28&30. NK cell levels can be influenced by 
stress, ethnicity and age. Rai et al suggested NK cell assessment should not be 
routinely performed outside a research context47. An anti-HY antibody is a 
relatively new concept within reproductive immunology. Epidemiological 
studies conducted by Nielsen et al in Scandinavian women suggest decrease in 
livebirth in index pregnancy following a prior birth of a boy48. In women with 
secondary recurrent miscarriages, presence of anti-HY antibody provides 
negative prognostic value. Other extended immune testing involves 
measurements of anti-nuclear antibodies, Th1/Th2 ratio, interleukins, cytokines 
and anti- HLA antibodies28, 29&30. The value of extended reproductive 
immunology testing in recurrent miscarriage remains debatable. These are not 
routinely recommended outside a research context. 
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Tests for sperm DNA fragmentation and sperm aneuploidy 
Suboptimal sperm results and raised DNA fragmentation are associated with 
subfertility. Ribas Maynou et al demonstrated that DNA fragmentation in 
sperm was significantly higher in male partners of women who had 
unexplained RM49.85% of the partners had DNA damage compared to 33% in 
fertile sperm donors.  
Robinson et al and Zhao et al suggested that DNA fragmentation testing should 
be routinely offered to couples following a diagnosis of recurrent 
miscarriage50&51. Sperm aneuploidy can also be performed by as part of 
investigations for male partners. 
 
Fetal karyotyping 
Fetal karyotyping is recommended for women with RM. It provides 
information about the current pregnancy loss. There are studies suggesting 
better prognosis for women in index pregnancies following an abnormal fetal 
karyotype. Incidence of aneuploidy may be as high as 78%52. Studies have used 
different techniques for fetal karyotyping including FISH and array CGH53.  
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A fetal chromosomal abnormality may be related to a sporadic event or 
inherited which may warrant further investigation in the parents. Ogasawara et 
al suggested that the risk of aneuploidy may decrease in women who 
previously had higher order miscarriages54. Stephenson et al suggested that 
aneuploidy rate is independent of maternal age17.  
 
 
Treatments for Recurrent Miscarriage 
 
The treatment options and strength of evidence for association with recurrent 
miscarriage are listed in table 1.4, table 1.5 and table 1.6.  
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Table 1.4 - Treatment options for the female partner 
Risk Factors Treatment option/s Strength of evidence 
for improving 
outcomes in 
recurrent miscarriage 
Genetic   
 Parental karyotyping17 
PGD Strong 
Donor gamete Strong 
   
Anatomic – Uterine abnormality   
 Uterine septum18 Resection Limited 
 Sub mucous fibroid19 Resection of fibroid Strong 
 Sub mucous polyp20 Resection of polyp Strong 
 Intrauterine 
adhesions21 
Division of adhesions Limited 
 Hydrosalpinx22 Salpingostomy Unknown 
 Cervical Insufficiency23 
– 2nd trimester 
Cervical cerclage  Strong 
   
Infections24  
 
 Chlamydia 
Antibiotics 
 
 
Limited 
 
 TORCH 
 Endometritis 
   
Endocrinological2   
 LPD Progesterone Limited 
 Hypothyroidism Thyroxine Limited 
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 Hyperthyroidism Anti-thyroid medications Limited 
 Abnormal glucose 
metabolism 
Metformin Limited 
 Raised PRL Dopamine agonists Limited 
 Reduced ovarian reserve IVF Limited 
 Evidence of PCOS Metformin Limited 
 Low Vit D Vit D supplementation Limited 
   
Immunological and autoimmune 
disorders25,26 
  
 LA 
Aspirin and LMWH 
Strong 
 
 Antiphospholipid 
antibodies  
 Beta 2 glycoprotein 
 Auto-antibodies 
Aspirin and LMWH 
Glucocorticoids 
Limited 
 Anti-nuclear antibodies or 
evidence of systematic 
rheumatological issue (for 
e.g. Systemic lupus 
erythematosus 
  
   
Thrombophilia26,27   
 Antithrombin 3 Aspirin and  
LMWH  
(Folic acid in addition for 
cases with MTHFR 
mutation) 
 
Limited 
 
 Factor V Leiden 
 Factor 2 prothrombin 
 MTHFR 
 Protein C 
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 Protein S Aspirin and  
LMWH  
 
Limited  PAI Polymorphism 
 C4M2 
   
Extended reproductive 
immunology28,29,30  
 
 Functional NK cell profile Steroids 
IVIL 
IVIG 
TNFα blocker 
G-CSF 
LIT 
Limited 
 
 TH1:TH2 Intracellular 
cytokine Ratio 
 LAD testing 
 HLA DQ – alpha  
 
 
 
 
Table 1.5 - Treatment options for the male partner 
Risk Factors Treatment option/s Strength of evidence for 
improving outcomes in 
recurrent miscarriage 
Genetic   
Parental karyotyping17 PGD Strong 
Donor gamete Strong 
   
Inherited Thrombophilia26,27   
 C4M2   
 
Aspirin and 
LMWH 
(Treatment is for the  
female partner) 
Limited 
 Factor V Leiden 
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Extended Reproductive 
immunology28,29,30 
 HLA DQ – alpha 
 
Steroids 
IVIL 
IVIG 
TNFα blocker 
G-CSF 
LIT 
(Treatment is for the 
female partner) 
Limited  LAD 
   
Sperm31,32   
 Sperm Aneuploidy PGS Limited 
 DNA Fragmentation Anti-oxidants Limited 
   
 
Table 1.6 - Treatment options for embryo aneuploidy  
Risk Factors Treatment option/s Strength of evidence for 
improving outcomes in 
recurrent miscarriage 
Genetic   
 Fetal karyotyping33 PGS/PGD Strong 
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Treatment for RM 
There are surgical, medical, IVF with PGS/PGD and non-pharmacological 
treatment options for RM. 
 
Surgical treatment options 
Surgical treatment are reserved for uterine abnormalities and limited to septate 
uterus. Other surgical procedures such as sub-mucous myomectomy, resection 
of endometrial polyp and division of intrauterine adhesions in cases of 
Ashermans syndrome are mostly related to subfertility rather than recurrent 
miscarriage. Pritts et al suggested treatment of submucosal fibroids 
significantly improves outcomes with recurrent pregnancy losses55. 
 
Kowalik et al in a cochrane review suggested that there is no prospective 
randomised data for different treatment options56; however, septate uterus in a 
clinical setting is routinely treated by hysteroscopic metroplasty. Clinicians 
prefer this technique as septate uterus carries worst reproductive outcome. The 
poor obstetric outcomes are directly proportional to the length of the septum as 
measured by MRI imaging techniques or as assessed at a routine hysteroscopy 
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Medical treatment options 
Anticoagulants: 
 
Antiphospholipid syndrome is the only treatable cause of thrombophilia. 
LMWH and aspirin together showed significant improvement in LBR 
compared to LMWH alone in a number of studies57,58,59&60.Even though there are 
some studies which suggest benefit for LMWH and aspirin for women with 
inherited thrombophilia, none of the trials were adequately powered61.ALIFE 2 
trial is currently in its recruitment phase and may provide further answers on 
efficacy of LMWH in inherited thrombophilia62.  
Skeith et al in a systematic review combined the results of 8 RCTs and found no 
benefit of LMWH for prevention of pregnancy loss in women with inherited 
thrombophilia and recurrent pregnancy loss63. This study suggested a RR of 
0.81 ; 95% CI 0.55-1.19). Mak et al and Empson et al found a benefit with 
anticoagulants to improve LBR in women with RPL64,65.  
 
Progesterone 
Progesterone preparation in the form of vaginal, oral and intramuscular 
preparations has been used for a long time and a number of studies have 
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suggested beneficial effect. Kumar et al66 suggested a reduction of miscarriage 
in index pregnancy following oral dydrogestone, RR= 2.4; CI, 1.3 to 5.9. 
Coomarasamy et al conducted the largest multicentre trial with vaginal 
progesterone in women with unexplained RM and concluded lack of benefit 
with progesterone67.  
 
Immunomodulatory agents 
Most of the medications in this group are new investigational medications. 
IVIG 
Intravenous immunoglobulin (IVIG) is a fractionated blood product used in 
inflammatory medical conditions. This is used as an off-license medication in 
treatment of recurrent miscarriage associated with abnormal immune response. 
Previously conducted RCTs suggested conflicting conclusions for benefit and 
no-benefit58&151. These trials had significant heterogeneity with limited number 
of patients and varying dose. Intravenous immunoglobulin has since been 
tested in a number of RCTs in unexplained RPL patients. The Cochrane review 
on immunotherapy in RPL by Wong et al concluded that IVIG was not 
beneficial in RPL68. Egerup at al in a systematic review and meta-analysis of 
IVIG in RPL suggested some benefit for women with secondary RM69.  Due to 
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the heterogeneity in the study groups, IVIG is not recommended for routine use 
in women with RPL as it is an expensive medication with serious systemic side 
effects which may include transfusion reaction, anaphylactic shock and 
hepatitis2. 
 
Glucocorticoids 
Prednisolone has a high affinity for glucocorticoid receptors. Uterine NK cells 
are different from peripheral NK cells by the presence of CD 56 and absence of 
CD 16 and CD 4. A number of studies suggested an increased number of 
uterine NK cells in endometrium of women with RM. These cells have specific 
glucocorticoid receptors which are bound by prednisolone. Laskin et al and 
Tang et al suggested an increase in LBR; however, this was not statistically 
significant70,71. There was also a high incidence of side-effects associated with 
administration of steroids.   
 
TNF Alpha inhibitors 
TNF alpha is a pro-inflammatory cytokine which can be blocked by monoclonal 
antibodies. One prospective cohort study suggested a slight reduction in first 
trimester miscarriages with an increased risk of birth anomalies72 . There are no 
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prospective RCT for TNF Alpha in women diagnosed with RM. RCOG 
recommends there is no evidence to use TNF alpha blockers outside a research 
context2.   
 
G-CSF 
These are hematopoietic cytokines which help with neutrophil differentiation 
and proliferation. Scarpellini et al suggested statistically significant increase in 
LBR after treatment with G-CSF73. A number of studies167-181 performed in 
women undergoing assisted conception and those who suffered recurrent 
miscarriage suggested improvement in outcomes. There was also evidence with 
an in vitro study using GM-CSF that there might be potential benefit166. 
 
IVF with PGS/PGD 
PGD aims at detecting single gene mutation with PCR or FISH. PGD is 
performed in RM where the parental karyotyping suggests chromosomal 
abnormality. PGS uses FISH and CGH to screen embryos for aneuploidy. 
Studies suggest that both PGD and PGS are beneficial for couple with combined 
RM and subfertility. In cases of RM, PGD may increase the LBR74,75, whereas 
PGS appears to be controversial76. 
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Non-pharmacological treatment 
Women after suffering repeated miscarriages are understandably under 
considerable amount of stress and anxiety. Stray-Pederson et al and Clifford et 
al highlighted the importance of non-pharmacological treatment involving 
early pregnancy reassurance scans and counselling in improving the outcomes 
in women with RM77,78.   
 
Uncertainties in recurrent miscarriage investigations and treatment 
Ideally, investigations should be performed if it can identify a risk factor or 
improve prognosis of a medical condition. However, RM being a diverse 
medical condition, the risk associations remain weak. There is no consensus 
amongst clinicians or professional bodies regarding the definition, 
investigations or managements. There are varied epidemiological and parental 
factors influencing the final outcome. Evidence for most of the genetic and 
epidemiological factors and their relation to RM are extrapolated from data 
from sporadic miscarriages and population registry studies.  
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Despite extensive investigation protocols, about half of RM cases remain 
unexplained. RCOG, ASRM and ESHRE have produced guidelines for 
investigation and management with limited consistency amongst them. Many 
investigations and treatment options are not advised by these professional 
bodies. This poses a significant clinical diagnostic dilemma for the clinician. 
Women with RM are vulnerable and desperate. Due to lack of NHS resources, 
women are often pressurised to undergo self –funded investigations that have 
limited or no evidence. For example, women are often labelled to have immune 
mediated miscarriages and are prescribed immunomodulatory medications. 
These treatment options for these may have harmful effects for the mother 
and/or the offspring. These can also cause significant financial stress for the 
couple with no clear benefit.  
 
The latest addition to this group of medications was recombinant granulocyte 
colony stimulating factor. Evidence from a single centre study using 
recombinant GSF treatment for unexplained RM suggested statistically 
significant increase in LBR73. There was a need for a definitive multicentre 
randomised study and therefore, I proceeded with RESPONSE study to 
investigate benefit of recombinant human granulocyte colony stimulating factor 
for women with unexplained RM.  
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Objectives of this thesis: 
1. To evaluate the efficacy of subcutaneous recombinant human 
granulocyte colony stimulating factor (rhG-CSF) versus placebo in 
pregnant women diagnosed with unexplained RM. 
2. To evaluate the safety, tolerability and immunogenicity of subcutaneous 
rhG-CSF in pregnant women with a history of unexplained RM.  
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CHAPTER 2 
IMMUNOLOGY OF EARLY PREGNANCY 
 
Introduction:  
Miscarriage is the most common complication in early pregnancy79. World 
Health Organisation (WHO) defines miscarriage as expulsion of fetus or 
embryo weighing 500 gram or less. Approximately 1 in 5 pregnancies end in a 
miscarriage, mainly in the first trimester. The most common reason for 
miscarriages is chromosomal abnormalities in the embryo80. In the UK, 200,000 
women suffer a miscarriage each year81. 
 
Miscarriage causes significant emotional, physical, social and financial 
implications in women, their partners and their immediate families2. Prevention 
of miscarriage is one of the most challenging areas in reproductive medicine. In 
spite of extensive and, sometimes, exhaustive investigations for both partners, 
only a half of miscarriages are found to be associated with a known cause or a 
major risk factor82 . 
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 When a cause or major risk factor is not identified, it is postulated that altered 
immune mediated mechanisms both at the fetal and maternal compartments 
may play a major role.   
Immuno-pathological evaluation of placenta by Kwak et al83 in women 
diagnosed to have miscarriages confirmed inflammatory infiltrate, fibrin 
deposition and evidence of thromboembolism at the feto-maternal interface84. 
These vascular and immunological factors and the cross-interactions may form 
the basis of immune mediated pregnancy loss. From an obstetric perspective, 
these changes can result in first and second trimester miscarriages, intrauterine 
growth restriction and /or pre-eclampsia in the second or third trimesters and 
intrauterine death. 
 
Insights for this theory are mainly from mice studies and also from failed 
human pregnancies85,86. Immunological investigations at the implantation site or 
placental interface in an ongoing human pregnancy are impractical and 
therefore, firm conclusions remain elusive. Therefore investigations, 
interpretation of results and treatment modalities used in reproductive 
immunology practice for immune mediated miscarriages remain controversial. 
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Immune system 
Any foreign body (antigen) that enters human body initiates an immune 
reaction. Human immune system functions with the help of different organs, 
cells and molecules; the primary mechanism of immune response is to produce 
antibodies which attaches to the antigen87 . 
The immune system provides a host defence mechanism. This forms the basis 
of prevention of infection, diseases and identification and destruction of 
malignant tumours. To activate appropriate response to different living, non- 
living and tumour promoting antigens, immune system needs to generate a 
wide range of antibodies88.   These antibodies should act and interact to produce 
effective mechanisms to eliminate any potential risk. 
 
The two ‘immune systems’ termed innate immune system and adaptive 
immune system provide  immune protection. In spite of innate and adaptive 
systems having different pathways, many cells have a physiological cross-
linkage and complement each other. This provides an adjuvant effect resulting 
in homeostasis. Different components and interactions of innate and adaptive 
immune systems are shown in Figure 2.1.  
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Figure 2.1 -  Components of innate and adaptive immunity.  
(Figure adapted from Nature reviews)89
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Innate Immune system 
This forms the initial trigger and rapid response mediated by recognition of the 
antigen. Antigen recognition is the hallmark of innate immunity90.  This is 
effective within minutes to hours and does the function of antigen recognition 
and destruction sub-clinically for the final ‘repair and healing’ process91.  
The mechanism involves different types of epithelial barriers, cell components 
and soluble molecules.  The components of innate compartment are mainly  
(1) Dendritic cells, 
(2) Macrophages and  
(3) NK cells. 
Antigen recognition in Innate Immunity: Key concepts 
a. Antigen contains pathogen associated molecular patterns (PAMPs).  
b. Mediators of innate immunity contain pattern recognition receptors 
(PRRs). These are identical receptors on all cells of same lineage . 
c. PAMPs directly or indirectly activate the PRRs and bind with them to 
initiate an acute inflammatory response. 
d. These inflammatory responses results in damage associated molecular 
patterns (DAMPs) 
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Adaptive Immune system 
This forms a later, highly individualised immune response if the innate 
immunity fails to recognise and destroy the antigen. Cell discrimination (self 
and non-self) is the hallmark of adaptive immune system. The adaptive 
immune process may take up to several days or weeks. A re-infection with the 
same antigen elicits a highly modified and effective individual microbial 
recognition resulting in immunological memory. Adaptive immunity can be 
humoral or cell mediated. The key components of adaptive immunity are 
mainly lymphocytes (also a small population of B lymphocytes which provides 
humoral immunity) and includes  
a. Cytotoxic T lymphocytes – CD8 expression, 
b. Helper T lymphocytes – CD 4 expression (has both Th1 cells and Th2 
cells) and  
c. Regulatory T cells – CD 4 expression 
 
Antigen recognition in adaptive immunity – Key concepts 
a. Following acute inflammation, dendritic cells capture the antigen and 
migrate to lymph nodes or spleen. This activates specific lymphocytes 
for the antigen. 
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b. Both T cell lymphocyte and B cell lymphocyte contain highly distinctive 
and specific receptors. They are encoded by somatic recombinant genes. 
They react in a highly diverse pattern. 
c. T cell lymphocyte function: Initially the microbial proteins get degraded 
to peptides. This binds to surface cell proteins named major 
histocompatibility complex (MHC) and forms the antigen presenting cell. 
This cell complex is identified by T cell lymphocyte receptor (TCR). 
d. B cell lymphocyte function : The microbial cell wall glycoprotein 
contains carbohydrates. This will be recognised and bound to B cell 
lymphocyte receptor (BCR) in its soluble form.  
e. Once activated, these lymphocytes can destroy the cell themselves 
(effector cells) or can initiate other cells to the inflammatory site. These 
cells also reach peripheral tissues and remains as memory T cells and B 
cells to maintain ‘immunological memory’.  
Maternal tolerance of fetus and immunology in a normal pregnancy 
Fusion of oocyte (with maternal chromosome derived antigens) and the sperm 
(with paternal chromosome derived antigens) results in fertilisation92.  
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Implantation of the fertilised oocyte (embryo) results in a pregnancy. Once 
implanted, the embryo is nurtured by the mother and a normal pregnancy 
results in a healthy offspring. Mammalian gestation is characterised by immune 
system ‘deactivation’ to allow the mother to accept and tolerate growth of 
embryo inside the uterus. This unique phenomenon is termed as viviparity93.  
Theoretically, embryo implantation process can activate the maternal immune 
system resulting in implantation failure. If so, a successful implantation is 
possible only by maternal immunosuppression. Viviparity, therefore, is 
important from an evolutionary perspective. It is essential that immune system 
adapts to the new environment and protects the mother (self) and the embryo 
(non-self).   
 
A number of studies 94-98 suggested that human decidua in successful pregnancy 
contains a high number of immune mediators from the innate and adaptive 
compartment. Early pregnancy can be considered as a pro-inflammatory stage. 
 
Further, mice and human studies confirmed depletion of inflammatory cells, 
mainly NK cells and dendritic cells results in placental dysfunction and early 
pregnancy failure95.  
37 
 
Matzinger et al and Bonney et al proposed that the ‘tissue damage capacity’ of 
antigen (degree of antigenicity) is more crucial than the self and non-self theory 
in initiating the inflammatory response99,100. Innate response medicated by was 
discussed earlier.  In a normal pregnancy there is inactivation of PAMPs –PRR 
response (innate immunity) and deactivation of TCR and BCR ligand 
production (adaptive immunity). These mechanisms result in deactivation of 
identification of danger signals resulting in rejection of the embryo.   
Series of complex immunological changes occurring during embryo 
implantation, trophoblast invasion and development can be considered as a 
state of immunomodulation rather than immune-suppression101,102. 
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Reproductive Immunology Paradox  
Over the last seven decades, many theories have evolved improving the 
understanding of early pregnancy immunology. Following observations from 
transplantation immunology, Medawar et al in 1953, introduced the concept of 
fetus as a semi – allograft103. Acceptance of this semi-allogenic graft results in 
pregnancy success. He proposed concepts of maternal tolerance of fetus based 
on 3 principles:  
(a) Anatomical separation of mother and fetus by a haemochorial placenta,  
(b) Immaturity of the fetal antigens and, 
 (c) Maternal immunosuppression.  
 
Beer at al, two decades later, identified the recognition of an early embryo by 
the maternal immune system and the resulting response104,105. This animal 
model study identified the role of HLA in early pregnancy maintenance. 
Further, different groups e.g. Billington et al106 suggested the theory of cell 
mediated immunosuppression and immune-protection by different cells in 
placenta, and HLA sharing by parents and its implications 
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The major breakthrough following Medawar et al proposal was the Th1/Th2 
hypothesis. Later studies identified the importance of placenta and its function 
in early pregnancy. The inflammatory interactions at this ‘local’ maternal-fetal 
interface and the relations to components in innate and adaptive immune 
system were studies in detail.  
 
Since Wegmann et al107 proposed the Th1:Th2 hypothesis, there has been 
significant changes to reproductive immunology research. Th1 cells are 
considered to be pro-inflammatory and Th2 cells to be anti-inflammatory. 
Based on this, an increased Th2 response (anti-inflammatory response) was 
considered beneficial for an on-going pregnancy whereas, an increased Th1 
response (pro-inflammatory response) was considered harmful to a pregnancy. 
This opinion gradually changed when researchers focused on research on 
components of innate and adaptive immune system. Based on their study, 
Moffet  et al suggested that immune adaptation during pregnancy was 
mediated primarily by a change in the NK cell population (innate system) 
rather than T lymphocytes (adaptive system)108. 
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Latest Evidence 
Latest research considers innate and adaptive immune system as an integral 
system, working in tandem to avoid the process of fetal rejection. They also 
support Medawar’s theory of immunosuppression by focusing on the anti-
inflammatory properties of T Reg cells (through cell mediated function of 
adaptive system). Maternal-Fetal interface favouring a normal outcome, 
includes maternal aspects such as  (a) de-activation of adaptive immune 
process, (b) immune tolerance and (c) tissue re-modelling (healing and 
repair)111. Fetal and placental aspects are (a) intact structure of placenta 
(maintained by NK cells), (b) restricted expression of MHC antigen and (c) 
secretion of anti-inflammatory proteins to enhance immune-tolerance112 . 
Trophoblast  
Haemochorial placenta can be considered as an organ with specific 
immunological, endocrinological and nutritional function. Trophoblast cells are 
the main component at the maternal-fetal interface and can be differentiated 
into 3 types (a) Villous cytotrophoblast that remains in the villi, (b) 
syncitiotrophoblast that lines the intervillious space and (c) non –villous 
cytotrophoblast which migrate into decidua and the uterine myometrium. 
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Innate immune system in pregnancy  
1. NK cells 
NK cells are lymphocytes with two important functions, namely are cell lysis 
and cytokine production. Studies confirm a reduction in the production of 
peripheral NK cells and levels of Interferon Gamma in early pregnancy113,114.  
These changes are consistent of an increased humoral response rather than a T 
cell medicated response. Peripheral NK cells express surface marker CD 56 dim 
16+. Some of these cells exhibit the function of lysis, others cytokine production, 
but most partake in both. Uterine NK cells are activated leucocytes which 
produce cytokines. They have similar characteristics to peripheral NK cells; 
however, they express CD56 bright CD 16 -115. 
 There is a significant increase in uNK cells after LH surge facilitating 
endometrial changes and implantation process. The major endometrial changes 
are remodelling of the spiral arteries, increase in production of angiogenic 
cytokines and VEGF. Uterine NK cells contain inhibitory receptors. These 
receptors bind to the MHC 1 a and 1 b on trophoblast and thus inhibit lysis. 
Therefore, in spite of the increased numbers of uNK cells in decidua, the non-
villous cytotrophoblast is not attacked. KIR and leptin like KIRs are example of 
inhibitory receptors116. 
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In spite of extensive studies conducted relating to NK cells and uterine NK 
cells, their role in human pregnancy is remains unclear98 .  
2. Macrophages 
Macrophages are found in decidua, placental trophoblast cells and extra-
placental membranes. The majority of macrophages reside in the decidua. They 
are mainly regulated by the hormonal changes in the uterine environment, 
mainly oestrogen. Their mechanism of action is somewhat related to the 
Th1/Th2 mentioned earlier. Activated macrophages produce 2 different types of 
cell, M1 and M2. M1 type is pro-inflammatory (secretes TNF and IL 12) and M2 
is anti-inflammatory (secretes steroids, IL - 4, IL-10 and IL - 13)117,118.  
Macrophages provide first line of immune defence.  They take part in   
a. a. Antigen identification and clearance,  
b. Placentation (by production of cytokines) and 
c. Produce immunosuppressive prostaglandins.  
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Macrophages identify antigens with the help of toll-like receptors and c type 
lectin receptors. These receptors activate a pro-inflammatory state in cases of 
blood borne infection and pre-eclampsia (raised levels of TNF, cytokines and 
PGE2)119. These events may explain the increased risk of pre-term labour 
associated with infections and pre-eclampsia120. 
3. Monocytes and Granulocytes 
Pregnancy associated increase in monocytes and granulocytes results in 
expression of free radicals and cytokines similar to patients with sepsis. This 
supports the theory of innate immunity activation in pregnancy. 
These changes are mediated by pregnancy related hormonal changes and 
placental proteins121. 
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4. Dendritic cells 
These are the most potent cell in the innate immunity and they work in close 
relation with T cell lymphocytes establishing a close link with adaptive 
immunity87. They are classified into 2 types: CD 83 + mature and CD 83 + 
immature, similar to M1 and M2 macrophages. Mature CD83+ cells are anti-
inflammatory and form a major part in immune tolerance and prevention of 
auto-immune diseases87. Immature CD 83 + cells, in turn, are pro-inflammatory. 
However, a group of immature CD 83+ cells in presence of inflammatory 
cytokines can differentiate into mature CD 83 + cells. Dendritic cell cytokines 
like G-CSF, GM-CSF, TGF beta and IL-10 can have anti-inflammatory function 
by disrupting the antigen presenting pathway88. 
 
Adaptive immune system in pregnancy 
The major component of the adaptive immune system is T lymphocyte. T 
lymphocytes can be divided as  
a. CD 8+ Cytotoxic T cells (CTLs), which can kill cells directly and  
b. CD 4+ T Helper cells (Th cells), which produce cytokines, can be sub 
classified into  
• Th1 cells – Pro-inflammatory (through IFN gamma and IL – 2) 
• Th17 cells – Pro-inflammatory 
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• Th2 cells – Anti-inflammatory (through IL-4, IL-5, IL-9, IL-10 and 
IL-13); and 
• T reg cells – Anti-inflammatory GILL MOR 
Key concepts  
a. During pregnancy, there is down regulation of Th1 cells, reducing 
Th1/Th2 ratio97. 
b. Hormonal changes favour Th2 mediated changes by producing anti-
inflammatory cytokines106. 
c. Placenta physiologically decreases pro-inflammatory cytokines112. 
d. Trophoblast cells produce indoleamine diogenase (IDO) to supress pro-
inflammatory T cell activity (by reducing tryptophan)99. 
 
 Maternal, Fetal/Trophoblast contribution during early pregnancy 
An embryo in early stages is protected from inflammatory proteins in the 
maternal system and fallopian tube by its shell, Zona Pellucida (ZP). Once, 
inside the uterus the embryo hatches itself and implantation process begins. 
This is the most crucial phase, initiating the first breach of superficial 
endometrium. 
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 An estimated 50% of embryos fail to implant; one hypothesis is that this is due 
to an exaggerated maternal immune response149. Under influence of 
progesterone (from an active corpus luteum), the embryo attaches and invades 
into the endometrium. This creates a decidual reaction in the endometrium118. 
This reaction stimulates a complex reaction at the level of uterine stroma under 
the influence of ovarian hormones, growth factor, cytokines, NK cells and 
dendritic cells118. These changes results in the reduction of maternal immune 
cells, mainly T lymphocytes and extra villous trophoblast cells enter the 
decidua118. The chorion membrane provides a physical barrier. The placenta 
releases fetal cells which gradually enters the maternal circulation resulting in 
fetal micro-chimerism. All the above changes results in immunosuppression 
(mediated by immune system activation). 
 
Major Histocompatibility Complex 
Major histocompatibility antigens are proteins which are expressed at the 
maternal–fetal interface122.  They are also known as transplant antigens as they 
play a role in graft rejection. These antigens help in distinguishing self and non-
self. These human leucocyte antigens are classified as: 
a. HLA 1a (HLA-A, HLA-B and HLA-C) helps in immune-recognition, 
b. HLA 1b (HLA-E, HLA-F, HLA-G ) helps in immune-acceptance and  
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c. HLA 2 (HLA-DP, HLA-DQ, HLA-DR) helps in immune-recognition 
Previous studies suggested trophoblasts do not express HLA 1a and HLA 2 to 
escape immune-recognition123.  
Trophoblasts produce HLA – 1b for immune acceptance and studies also 
suggested this prevents lysis of trophoblast cells by uNK cells. More recent 
studies confirm presence of fetal HLA in maternal serum and therefore the 
pregnancy equilibrium is maintained by maternal immune system ‘priming’ (to 
accept the fetus) rather than ‘ignorance’124,125.   
 
Discussion 
Advances in molecular techniques have helped in identifying new cells, their 
subtypes and proteins on a regular basis. This has improved the understanding 
of concepts and mechanisms in reproductive clinical immunology but equally, 
has made it more can be challenging, even to the experts108. Evidence suggests 
link to immune mediated dysfunction to unexplained sub-fertility, recurrent 
miscarriages, pre-eclampsia and preterm labour126.  
Any disturbances of  the innate or adaptive immune system at the maternal-
fetal interface may result in pregnancy failure. Theoretically, approaches to 
maternal immunomodulation by novel medications may improve the outcome 
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of immune mediated pregnancy disorders. However, a uniform understanding 
of immune mechanisms is needed. Until then unproven and anecdotal 
treatment options as part of immune suppression should be used with caution, 
and only within research settings. 
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CHAPTER 3 
SYSTEMATIC NARRATIVE REVIEW OF AVAILABLE EVIDENCE OF 
GRANULOCYTE COLONY STIMULATING FACTORS IN 
REPRODUCTIVE MEDICINE 
 
Introduction  
Natural fertility potential in humans is surprisingly low. It has been estimated 
that about 70% of human conceptions do not reach viability of which 50% are 
lost before or during menstrual cycle127.Repeated episodes of miscarriages can 
affect 1% of women in the childbearing age128,129.  
 
The most common reason for miscarriage is chromosomal abnormalities in the 
fetus, the risk of which increases with advancing maternal age. Other reasons 
include parental chromosome translocations130, intra-uterine infections131,132 , 
endocrine abnormalities133,134 , uterine malformations135, antiphospholipid 
antibody syndrome or other autoimmune conditions136. 
 
Investigations are reported to be normal in about half of the couples 
undergoing screening for recurrent miscarriages137. Such couples are said to 
have unexplained RM. This condition has generated great interest in the field of 
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reproductive medicine research. One proposed cause of unexplained recurrent 
miscarriages relates to immune dysfunction or allo-immune responses138. 
Several immune mechanisms for reproductive failure have been described. The 
most debated theory is the prevalence of increase in pro-inflammatory 
cytokines and reduction in anti-inflammatory cytokine during pregnancy which 
results in a high Th1:Th2 ratio. This may result in the rejection of the fetus or 
the ‘embryonic allograft’139.  
 
Over the last 40 years, assisted conception techniques have gained popularity. 
IVF and IVF techniques with ICSI are practised for treatment of subfertility for a 
wide variety of reasons including RM. 
 
HFEA statistics140 suggests live birth rate per ET per cycle of IVF/ICSI ranging 
from 41.8% (for a woman under the age of 35) to 12.4% for women between the 
ages of 43-44.   
 
Repeated failure of embryo implantation in assisted reproductive techniques 
(ART) can be defined as failure to achieve a pregnancy after a total of four good 
quality embryos were transferred over 3 cycles141. Similar to RM, there are 
discrepancies regarding definitions, investigations and management of 
recurrent implantation failure (RIF). There are many reasons for RIF including 
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factors relating to sperm, oocyte, embryo, uterus and fallopian tube. Majority of 
the factors remain unexplained. In spite of major advancement in assisted 
reproductive techniques, the implantation rates still remain relatively low. 
Embryo implantation is the rate limiting step in assisted conception treatment 
142. The final outcome is determined by a good quality embryo transferred into a 
receptive endometrium. A receptive endometrium supports the transformation 
of endometrial cells into decidua cells, blastocyst invasion and development of 
placenta143.  Receptivity is facilitated by immune cells, growth factors, cytokines, 
and hormonal changes144,145. These complex immune mechanisms at the 
endometrial level are important and crucial in implantation process146.  
 
There are many immunological factors considered to be crucial for 
establishment and maintenance of pregnancy. Clinicians use treatment options 
which have limited evidence to improve the immunological milieu147  . This is 
with a view to decrease RM within natural conceptions and also to try and 
improve outcomes with ART.  There is considerable debate for the value of 
immunological treatment.  
 
The commonly used immune modulation treatment includes progesterone, 
corticosteroids, paternal lymphocyte infusion therapy, intravenous intralipid 
infusion and anti – TNF drugs. Previously, clinicians used paternal leukocyte 
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transfusion148, trophoblast membrane vesicle extracts149 and seminal plasma 
suppositories150. Intravenous immunoglobulin immunonotherapy150-152 is still 
used in clinical practice when intravenous intralipids are found to be 
ineffective.   
 
However, all these treatments have not received general acceptance as the 
published results are controversial. A recent meta-analysis has shown that none 
of these therapies showed significant effects on patients with unexplained 
RM153,154.  
 
A recent addition to this group of medications is granulocyte colony 
stimulating factor. The aim of this systematic narrative review was to evaluate 
the effectiveness of granulocyte colony stimulating factor in reproductive 
medicine. 
 
G-CSF  
Granulocyte colony-stimulating factor is a cytokine, first recognized and 
purified in mice in 1983. Human G-CSF (hG-CSF) was cloned in 1986155,156. The 
biological activities of hG-CSF are mediated by a specific receptor on the cell 
surface of responding cells. This receptor (G- CSF-R) is present on myeloid 
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progenitor cells, myeloid leukaemia cells, mature neutrophils, platelets, 
monocytes, lymphoid cells and some T cells and B cells. 
 
G-CSF is produced by bone marrow, stromal cells, endothelial cells, 
macrophages and monocytes157-159. In female reproductive tract, it is naturally 
found in endometrium, ovarian follicles and fallopian tube epithelial cells160-161.  
 
The structure and molecular characteristics of recombinant human granulocyte 
colony stimulating factor is shown in Figure 3.1. 
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Figure 3.1 -  G-CSF contains approximately 20 kD glycoprotein with 174 
amino acids arranged in four anti-parallel a helices. The gene   for G-CSF is 
found on chromosome 17 q 21-22. 
(Figure courtesy: NORA Therapeutics)162.
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The main function of G-CSF is to stimulate the proliferation and differentiation 
of neutrophils in the bone marrow and control their release157. These activities 
are mediated by receptors on cells of haemopoitic cell lineage and in cases 
specific to reproduction by receptors found in lower genital tract159,160(fallopian 
tube, follicular cells, placental cells and trophoblastic cells)  
 
Studies in both humans and animals have shown that G-CSF improves 
endometrial thickness, ovarian follicular function and oocyte quality, which in 
combination enhances embryo implantation159-161. These actions may result in 
successful pregnancy outcomes by reducing pregnancy failure. In-vivo and in-
vitro studies have shown low levels of G-CSF concentration in endometrial cells 
and follicular cells in subjects with pregnancy losses. G-CSF helps in blastocyst 
development and G-CSF mediated changes on decidual cells, dendritic cells, 
Th-2 cytokine secretion and activation of T regulatory cells may help in 
implantation161.  
 
The basis of immune mediated pregnancy loss is conventionally explained by 
an imbalance in T helper 1 : T helper 2 ratios, dysfunction of human T cells, N-K 
cells cytotoxicity and human leucocyte antigen incompatibility. The exact 
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mechanisms of anti-abortive actions of G-CSF in animal and human studies are 
not yet known.  
 
Materials and methods 
The aim of the review was to identify all studies investigating the use of G-CSF 
in women undergoing IVF or use of G-CSF during pregnancy for any 
indication. The review was conducted and reported in adherence with PRISMA 
statement163. No ethical approval was needed. 
 
Identification of studies 
The electronic databases CINAHL, Cochrane, EMBASE and Medline (from 
inception to April 2017) were used to perform the literature search. The 
following keywords and MeSH subheadings were used in the search strategy: 
‘G-CSF’, ‘granulocyte colony stimulating factor’ AND ‘recurrent miscarriage’, 
‘assisted conception’ OR ‘IVF’ OR ‘reproductive medicine’. The basic search 
strategy was adapted to suit the database being searched. The search was 
restricted to humans and females. Bibliographies of relevant primary articles 
were also searched to identify any articles missed by the electronic searches.  
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Study selection and data extraction 
 
Studies were selected following a two-step process. Firstly, the citations 
identified by the electronic bibliographic database searches were screened, 
based on their titles and abstracts. Full text papers of eligible abstracts were 
retrieved. Once full text papers had been located, we determined whether they 
fulfilled our predetermined inclusion criteria:  
Population: women who received G-CSF during pregnancy or as part of ART. 
Intervention: G-CSF (any route of administration) 
Comparator: no treatment, another therapy 
Outcome: reduction in miscarriage, increase in endometrial thickness, 
improvement in ART outcomes, improvement in pregnancy outcomes. 
 
All randomised controlled trial (RCT), cohort studies and case control studies 
were included and case reports and reviews on the subject were excluded.  Any 
studies where women did not administer exogenous G-CSF were excluded 
from the final analysis. 
 
Two reviewers (AE and BK) independently assessed the full text papers to 
determine if they met the above criteria. Any disagreements regarding the 
eligibility of a paper were resolved by consensus.  The full manuscripts of the 
included titles and abstracts were retrieved for further assessment. If there were 
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duplicate studies, the most recent and complete version were chosen. Data from 
the manuscripts were extracted onto a pre-designed pro-forma which included 
study design, sample size and population, indication for G-CSF , intervention, 
dose, route of administration, control and outcome. The literature search was 
thorough and without language restrictions. 
 
 
Quality assessment of studies  
The methodological quality of all manuscripts included in the study was 
assessed. Quality was defined as the confidence that the study design, conduct 
and analysis minimised bias in the estimation of effectiveness. The 
methodological quality of the RCTs included was assessed using the Cochrane 
risk bias score. The methodological quality of the non-RCT studies included 
was assessed using the Newcastle–Ottawa scale. A non-randomised study was 
considered to be of a high quality if it provided information on selection, 
comparability, exposure and outcome of the study participants. A maximum of 
one point was awarded for all items except for comparability which scored a 
maximum of two points. The score ranged from 0 to 7, with a score of either 0 
or 1 for each item. The quality assessment is detailed in figure 3.3 and figure 3.4 
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Results 
Figure 3.2 show the PRISMA diagram of the review process. The search of 
electronic databases produced 2501 citations. Two thousand four hundred and 
fifty four studies were excluded after examination of titles and abstracts as they 
did not meet the inclusion criteria. 
 
Forty seven full manuscripts were retrieved of which 30 further studies were 
excluded. Five were excluded as they were duplicate publications, six studies 
investigated other immunomodulatory treatment in conjunction with G-CSF, 11 
citations investigated effects of endogenous G-CSF and did not have any 
relevant data and eight were excluded as they were case reports. 
 
Thus a total of 17 studies were included in the review. 
 
The study characteristics of 17 studies are presented in table 3.1. The 17 studies 
can be divided into two groups; those which investigated efficacy of G-CSF in 
IVF treatment (12 studies) and those which investigated efficacy of G-CSF in 
RM (five studies)
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Figure 3.2 - Study selection for review of G-CSF in reproductive medicine 
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Figure 3.2a: Cochrane risk bias score for included studies 
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Newcastle Ottawa quality assessment for included studies in this review 
Studies Selection Comparability Outcome Total 
score 
Representativeness 
of exposed cohort 
Selection of 
the non-
exposed 
cohort 
Ascertainment 
of exposure 
Assessment of 
outcome 
Adequacy of 
completeness 
of follow up 
Gleicher et al, 2013 * * _ * * * 5 
Kunicki et al, 2014 * * _ * * * 5 
Lee et al, 2016 * * * * _ * 5 
Scarpellini et al, 
2012 
* * * * * * 6 
Tehraninejad et al, 
2015 
* * _ * * * 5 
Wurfel et al, 2013 * _ _ _ _ * 2 
Xu et al, 2015 * * * * * * 6 
Zeyneloglu et al, 
2013 
* * _ * * * 5 
Boxer et al, 2015 * _ _ _ _ * 2 
Santjohanser et al, 
2013 
* * * * * * 6 
Zeidler et al, 2014 * _ _ _ _ * 2 
Figure 3.2b: Newcastle Ottawa quality assessment for Included studies 
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Reference 
(Year) 
Study design 
(Country) 
Sample size 
&   
Population 
Indication 
for  
G-CSF 
Intervention 
&  
Administration 
route 
Control Results  
& 
Outcome 
Aleyasin et 
al., (2016) 
Randomised  
Trial 
(Iran) 
112 women 
with repeated 
IVF failures 
To improve 
IVF outcomes 
300 micrograms 
of G-CSF instilled 
into uterine 
cavity 1 hr before 
ET 
Controls had no 
additional 
treatment 
The successful 
implantation (18% vs 
7.2%, P=0.007), chemical 
pregnancy (44.6% vs 
19.6%, P=0.005), and 
clinical pregnancy (37.5% 
vs 14.3%, P=0.005) rates 
were significantly higher 
in the intervention group 
than in the control group. 
Administration of G-CSF 
improved implantation 
rates, chemical pregnancy 
and clinical pregnancy. 
Barad et 
al., 
(2014) 
Randomised 
controlled 
study 
(USA) 
141 women 
undergoing 
IVF  
To improve 
endometrial 
thickness, 
implantation 
rates and 
clinical 
pregnancies 
300 micrograms 
of G-CSF instilled 
into uterine 
cavity on day of 
hCG trigger 
Controls had  1 
ml of normal 
saline instilled 
into uterine 
cavity on day of 
hCG trigger 
Endometrial thickness 
statistically significantly 
increased over the 5-day 
observation period for 
the whole group by 
approximately 1.36 mm. 
Administration of G-CSF 
did not result in 
Table 3.1 – Characteristics of included studies of G-CSF in ART  
64 
 
statistically different 
improvement in 
endometrial thickness, 
implantation rates or 
clinical pregnancies. 
Davari-
tanha et 
al., 
(2016) 
Randomised 
controlled 
study 
(Iran) 
100 women 
with repeated 
IVF failures 
To improve 
implantation 
rates and 
clinical 
pregnancies 
in IVF 
300 micrograms 
of G-CSF instilled 
into uterine 
cavity on day of 
oocyte retrieval  
Controls had 1 
ml of normal 
saline instilled 
into uterine 
cavity on day of 
oocyte retrieval 
17 patients had a positive 
pregnancy test after 
embryo transfer [10 (25%) 
in G-CSF; 5 (12.5%) in 
saline; and 2 (10%) in 
placebo group]. The 
mean of abortion rates 
was 17.6% (3), two of 
them in G-CSF, one in 
saline group. The IR was 
12.3% in G-CSF, 6.1% in 
saline and 4.7% in 
placebo group. 
Administration of G-CSF 
improved implantation 
rates, chemical pregnancy 
and clinical pregnancy. 
Eftekhar et 
al., 
(2016) 
Randomised 
controlled 
study 
(Iran) 
100 women 
who had 
repeated IVF 
failures  
To improve 
implantation 
rates and 
CPR  
300 micrograms 
of G-CSF instilled 
into uterine 
cavity on OR day 
Controls had no 
additional 
treatment 
Administration of G-CSF 
did not results in 
improvement of 
implantation rate or CPR. 
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Eftekhar et 
al., 
(2016) 
Randomised 
controlled 
study 
(Iran) 
90 women 
who had 
repeated IVF 
failures 
To improve 
clinical 
pregnancies 
in IVF 
300 micrograms 
of G-CSF instilled 
into uterine 
cavity on day of 
oocyte retrieval  
 
Controls had no 
additional 
treatment 
The pregnancy outcome 
in GCSF group was 
improved significantly 
(p=0.043). Administration 
of G-CSF  improved 
implantation rates, 
chemical pregnancy and 
clinical pregnancy. 
Gleicher et 
al., (2013) 
 
 
 
Prospective 
observational 
study 
(USA) 
21 women 
who had 
endometrium 
less than 7 
mm 
undergoing 
IVF treatment 
To improve 
endometrial 
thickness in 
IVF 
 
 
300 micrograms 
of G-CSF instilled 
into uterine 
cavity on day of 
hCG (and if 
needed on day of 
oocyte retrieval) 
No controls With 5.2 ± 1.9 days 
between G-
CSF perfusions and 
embryo transfers, 
endometrial thickness 
increased from 6.4 ± 1.4 to 
9.3 ± 2.1 mm (P < 0.001). 
The Δ in change was 2.9 ± 
2.0 mm, and did not vary 
between conception and 
non-conception cycles. A 
19.1% ongoing clinical 
pregnancy rate was 
observed, excluding one 
ectopic pregnancy. 
Administration of G-CSF 
improved endometrial 
thickness and is an 
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effective treatment for 
chronically thin 
endometrium.  
Kunicki et 
al., (2014) 
Prospective 
observational 
study 
(USA) 
37 women 
with 
endometrium 
less than 7 
mm 
undergoing 
IVF treatment 
To improve 
endometrial 
thickness in 
IVF 
 
300 micrograms 
of G-CSF instilled 
into uterine 
cavity on day of 
hCG (and if 
needed on day of 
oocyte retrieval) 
No controls Endometrium expanded 
significantly from 6,86 ± 
1,65 to 8,80 ± 1,14 mm in 
the first group (who 
conceived) and from 6,71 
± 1,80 to 8,33 ± 1,85 mm 
in the second, 
respectively. 
Administration of G-CSF 
improved endometrial 
thickness after 72 hrs of 
instillation 
Lee et al., 
(2016) 
Retrospective 
observational 
study 
(Korea) 
50 women 
with  
endometrium 
less than 8 
mm on day 
of HCG 
To improve 
endometrial 
thickness in 
IVF 
300 micrograms 
of G-CSF instilled 
into uterine 
cavity on day of 
hCG or on day of 
oocyte retrieval 
No controls The overall clinical 
pregnancy rate was 
22.0%, the implantation 
rate was 15.9%, and the 
ongoing pregnancy rate 
was 20%. The clinical 
pregnancy rate (41.7% vs. 
15.8%), the implantation 
rate (26.7% vs. 11.7%), 
and the ongoing 
pregnancy rate (41.7% vs. 
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13.2%) were higher 
when G-CSF was instilled 
on the triggering day 
than when it was instilled 
on the retrieval day. 
Administration of G-CSF 
improved endometrial 
thickness.   
Scarpellini 
et al 
(2012) 
Prospective 
observational 
study  
(Italy) 
109 women 
with RIF 
To improve 
IVF outcomes 
58 women treated 
with daily 
subcutaneous 
injection of 60 mg 
of G-CSF from ET  
51 women 
treated with 
daily SC  
injection of 
saline  from day 
of ET 
Administration of G-CSF 
improved IVF outcomes 
in women with previous 
implantation failure. 
Tehraninej
ad  
et al 
(2015) 
Prospective 
observational 
study  
(Iran) 
15 women 
undergoing 
IVF treatment 
with thin 
endometrium 
To improve 
endometrial 
thickness in 
IVF 
300 micrograms 
of G-CSF instilled 
into uterine 
cavity on day of 
OR or 5 days 
before ET  
No controls  The endometrial 
thickness reached from 
3.593±0.251 mm to 7.120 ± 
0.84 mm. Administration 
of G-CSF may improve 
endometrial thickness.  
  
Wurfel et 
al;  
(2013) 
Retrospective 
cohort study 
(Germany) 
 
301 women 
with RIF 
To improve 
IVF outcomes 
Varying doses Not clear Administration of G-CSF 
improved IVF outcomes 
in women with RIF 
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Xu et al., 
(2015) 
Prospective 
observational 
study 
(Korea) 
82 women 
undergoing 
frozen 
embryo 
transfer after 
IVF treatment 
To improve 
endometrial 
thickness in 
IVF 
Group A  
300 mcg of G-CSF 
instilled into 
uterine cavity in 
follicular phase 
 
Group B  
G-CSF as above 
plus endometrial 
scratching 
Controls had no 
additional 
treatment 
Significantly higher 
embryo implantation and 
clinical pregnancy rates 
were observed in the G-
CSF group compared 
with the control group 
(31.5% versus 13.9%; P < 
0.01; 48.1% versus 25.0%; 
P = 0.038, 
respectively)Administrati
on of G-CSF improved 
endometrial thickness, 
implantation rates and 
clinical pregnancy rates.  
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Zeynelogl
u et al 
(2013) 
Prospective 
observational 
study 
(Turkey) 
32 women 
with RIF 
To investigate 
ideal route of 
G-CSF 
administration 
Group A  
9 women with 
intrauterine 
administration of 
48 miu/0.5 ml on 
day of HCG  
Group B  
15 women had 
subcutaneous 
injection of G-
CSF on a dose  of 
100000 iu/kg 
from day of 
oocyte retrieval 
for 15 days 
Group C  
8 women had 
both intrauterine 
and 
subcutaneous 
doses  as above 
 
 
 
 
 
No controls G-CSF is a safe 
medication to increase 
pregnancy rates in IVF 
treatment and dual 
administration seems to 
be best 
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Reference 
(Year)  
Study design 
(Country) 
Sample size 
&   
Population 
Indication 
for G-CSF 
Intervention 
&  
Administration 
route 
Control Results  
& 
Outcome 
Boxer et al.,  
(2015) 
Retrospective 
observational 
study 
(USA) 
107 women 
with 224 
pregnancy 
events with 
chronic 
neutropenia 
To treat 
chronic 
neutropenia 
Varying doses 
ranging from 
daily/alternate days 
to twice weekly 
subcutaneous 
injections or no 
doses depending on 
severity of 
neutropenia  
 
No controls Administration of 
G-CSF increases 
WBC subsets. 
Decrease in 
abortions in G-CSF 
group. There were 
no adverse effects  
 
Santjohanser 
et al.,  
(2013) 
Retrospective 
cohort study 
(Germany) 
 
127 women 
with RM (2 or 
more 
miscarriages) 
undergoing 
IVF treatment 
To improve 
outcomes in 
RM  
Group A - 
Subcutaneous 
injection of G-CSF, 
34 miu per week 
from embryo 
transfer until 12 
weeks of pregnancy. 
Group B - Had 
medications which 
included steroids, 
IVIG or LMWH  
 
Controls had no 
additional 
treatment 
The LBR of patients 
and the subgroups 
differed 
significantly (G-
CSF 32%, subgroup 
1 13%, subgroup 2 
14%)Administration 
of G-CSF  resulted 
in statistically 
significant 
improvement in 
LBRs. 
Table 3.2 – Characteristics of included studies of G-CSF in recurrent miscarriage 
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Scarpellini  et 
al., 
(2009) 
Randomised 
controlled 
study 
(Italy) 
68 women 
with 
unexplained 
primary RM 
(4 or more 
consecutive 
miscarriages)  
To prevent 
embryo 
demise 
Subcutaneous 
injection of G-CSF, 1 
microgram/kg/day 
from as soon as 6 
days after ovulation 
until 9 weeks of 
gestation.  
Controls had 
saline injections 
from as soon as 
6 days after 
ovulation until 9 
weeks of 
gestation. 
 In the group treated 
with G-CSF, 29 out 
of 35 (82.8%) 
women delivered a 
healthy baby, 
whereas in the 
placebo group, this 
figure was only 16 
out of 33 (48.5%) (P 
= 0.0061, odds ratio 
= 5.1; 95% CI 1.5-
18.4) 
Administration of 
G-CSF  resulted in 
statistically 
significant decrease 
in miscarriages and 
significant 
improvement in 
LBRs 
Wurfel et al;  
(2013) 
Retrospective 
cohort study 
(Germany) 
 
308 women 
with RM 
To prevent 
miscarriages 
Varying doses Not clear Administration of 
G-CSF  resulted in 
statistically 
significant 
improvement in 
LBRs 
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Zeidler et al; 
(2014) 
Retrospective 
observational 
study 
(SCNIR) 
38 pregnancy 
events 
already 
diagnosed 
with chronic 
neutropenia  
 
To treat 
chronic 
neutropenia 
Varying doses or no 
doses according to 
severity of 
neutropenia 
No controls Administration of 
G-CSF did not result 
in improvements in 
pregnancy 
outcomes.  
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G-CSF in IVF treatment 
It is hypothesised that granulocyte colony stimulating factor improves ART 
outcomes. The effects of G-CSF on oocyte quality, embryo development, 
embryo implantation and thin endometrium have been evaluated both by 
animal and human studies. 
 
In early 2000, Wurfel et al conducted studies which suggested benefits of G-CSF 
on implantation, embryo development and increase in pregnancy rates164. 
Further studies by Frydman et al confirmed increase in implantation rates and 
live birth rates. Ledee et al followed up this study and suggested that oocyte 
grading, embryo morphology and implantation rates were better when the 
levels of endogenous G-CSF were higher. Surprisingly these effects were not 
associated with any other hormone or cytokine165.    
 
Improvement in embryo quality was suggested by Ziebe et al in a double blind 
RCT in 1149 embryo transfer events within IVF treatment166. This suggested a 
significant improvement in implantation rates and LBRs. A number of studies 
suggested improved outcomes in ART with use of G-CSF in women with 
implantation failure by improving endometrial thickness167. This may be by the 
proliferation and differentiation of endometrial cells by CAMP increase in 
stromal cells167. 
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Aleyasin et al., performed a RCT  to assess the efficacy of  systemic  G-CSF in 
112 women who underwent IVF treatment further to having a diagnosis of 
recurrent implantation failure168. The rates for implantation (18% vs 7.2%, P = 
0.007), chemical pregnancy (44.6% vs 19.6%, P = 0.005), and clinical pregnancy 
(37.5% vs 14.3%, P = 0.005) were significantly higher in the G-CSF group. 
Adjustments for different treatment variables were applied and the authors 
concluded that administration of systemic G-CSF before implantation 
significantly increases the IVF outcomes. 
 
Barad et al., performed a study to assess the efficacy of intrauterine instillation 
of G-CSF to improve endometrial thickness and implantation rates in 141 
unselected women undergoing IVF treatment169. There was an average increase 
of endometrial thickness by 1.36 mm in the G-CSF group; however, this was not 
statistically significant when compared to the control group. This study did not 
suggest improvement in IVF outcome with use of G-CSF. 
 
In a randomised control trial of 100 women undergoing IVF treatment, Davari-
tanha et al. evaluated G-CSF to improve IVF outcomes170. Unlike findings 
suggested by Barad et al., intrauterine instillation of G-CSF as a single dose on 
day of oocyte retrieval resulted in significant improvement in implantation 
rates and clinical pregnancies.  
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Eftekhar et al., conducted a randomised control study in 100 women 
undergoing IVF treatment. All women were assessed to have normal 
endometrial thickness prior to the study171. Intrauterine instillation of G-CSF 
did not result in a statistically significant change between the 2 groups. The 
authors concluded that G-CSF does not improve outcomes in women 
undergoing IVF with normal endometrial thickness. The same author group 
conducted a further RCT in 90 women undergoing IVF treatment after being 
diagnosed with RIF. Using the same study technique, the authors concluded 
that use of intrauterine instillation of G-CSF resulted in a statistically significant 
improvement in pregnancy outcomes (p=0.043). 
 
In a prospective observational cohort study of 21 women, Gleicher et al. 
assessed efficacy of G-CSF to improve endometrial thickness172. 300 mcg of G-
CSF was instilled using an intrauterine catheter on day of ovulation trigger. In 
this study of a highly selected participants, there was statistically significant 
increase in endometrial thickness, p<0.001. These women failed to achieve this 
increase with other conventional treatment techniques used within IVF 
treatment prior to this study. 
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Kunicki et al, in a prospective cohort study followed the same protocol as 
Gleicher et al in 37 women with an endometrial thickness less than 7 mm143. 
There was no statistically significant difference in endometrial thickness before 
and after the infusion. A further subgroup analysis was conducted after 
positive pregnancy test which suggested that women who conceived had 
thicker endometrium and the authors propose that the endometrium may have 
thickened after a delayed response to G-CSF infusion.   
 
Lee et al. also followed a similar study technique in a retrospective 
observational study in women with endometrial thickness less than 8 mm in 
those with one previous IVF failure173. The mean endometrial thickness was 
7.2±0.6 mm on ovulation trigger day which increased to 8.5±1.5 mm on the 
embryo transfer day in the G-CSF group. This was statistically significant, 
p<0.001. The G-CSF group had a higher rates for clinical pregnancy (41.7% vs. 
15.8%), implantation rate (26.7% vs. 11.7%), and ongoing pregnancy rate (41.7% 
vs. 13.2%).  
 
Scarpellini et al. conducted an observational study in 109 women undergoing 
IVF after a diagnosis of RIF174. 58 women were treated with a dose of 60mg/day 
from day of embryo transfer for 40 days. There was a statistically significant 
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increase in pregnancy rate in the G-CSF group (43.1%) versus the control group 
(21.6%), p<0.001.  
 
Tehraninejad et al. observed effects of G-CSF on endometrial thickness 
improvement in 15 women undergoing IVF treatment175. These women were 
previously diagnosed to have thin endometrium resistant to treatment 
conventionally used in IVF treatment. The authors suggest that intrauterine 
instillation of G-CSF prior to embryo transfer improves endometrial thickness. 
 
Wurfel et al. conducted a series of studies investigating efficacy of G-CSF in 
ART  and further summarised the data in a retrospective analysis of 301 women 
who underwent IVF treatment176. These women were otherwise diagnosed with 
repeated implantation failure. Varying doses were used within the study using 
different preparation of G-CSF and GM-CSF and the authors suggested 
significant improvement in live birth rates. 
 
Xu et al., in a prospective study divided 82 women undergoing frozen embryo 
transfer into 3 groups and assessed the efficacy of GCSF to improve ART 
outcomes in conjunction with endometrial scratching177. There was a slightly 
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higher clinical pregnancy and live birth rates in the G-CSF with endometrial 
scratch subgroup than the G-CSF only subgroup. The clinical pregnancy rates 
and live birth rates were 53.8 % and 38.5% in the G-CSF plus endometrial 
scratch group. The clinical pregnancy rates and live birth rates in the G-CSF 
only group was 42.9% and 28.6%, respectively. Compared to the control group, 
there were significantly higher embryo implantation rates in G-CSF group 
(31.5% versus 13.9%; P < 0.01 compared to the placebo group.  The clinical 
pregnancy in the G-CSF only group was 48.1% versus 25.0%; P = 0.038 in the 
control group.  
 
Zeyneloglu et al., in a prospective observational study investigated the ideal 
route of administration and grouped 32 women into 3 groups to receive 
intrauterine, subcutaneous or both respectively178. The pregnancy rates were 
44%, 60% and 75% respectively. The authors concluded that dual 
administration of G-CSF may result in improvement in ART outcomes. 
 
G-CSF in Recurrent miscarriage 
Boxer at al., did a retrospective observational analysis on severe chronic 
neutropenia international registry (SCNIR) in 2015 and identified 107 women 
with 224 pregnancy events179. Varying doses of G-CSF started were started at 
different time points in pregnancy. This study suggested no improvement in 
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pregnancy outcome, however, confirmed that there was no increase in adverse 
events with use of G-CSF during pregnancy. 
 
Wurfel et al., summarised evidence of efficacy of G-CSF in RM in a 
retrospective analysis in 308 women who were diagnosed with RM176. These 
women had varying doses and preparations of G-CSF within the study period. 
The study suggested a significant improvement in live birth rates (78.1%).  Both 
G-CSF and GM-CSF were used in this study. 
 
Santjohanser et al., conducted a retrospective cohort study in 127 women who 
had 2 or more previous miscarriages180. All these women had IVF treatment and 
were divided into two groups, group A receiving G-CSF and group B, receiving 
other medications to include steroids or IVIG or LMWH. The authors 
concluded a significant increase in LBRs in the G-CSF group. 
 
Scarpellini et al., conducted the first randomised control study (n=68) to assess 
the efficacy of G-CSF in recurrent miscarriage73. The participants were 
diagnosed to have at least 4 previous miscarriages. They were randomised to G-
CSF vs placebo in a 1:1 ratio. The study suggested significant reduction in 
miscarriages and a statistically significant increase in live birth rates. In the G-
80 
 
CSF group, the live birth rate was 82.8% whereas in the placebo group, the live 
birth rate was 48.5%, P = 0.0061, odds ratio = 5.1; 95% CI 1.5–18.4.  
 
Another observational analysis on SCNIR database by Zeidler et al., in 38 
pregnancy events investigated G-CSF use in women with chronic 
neutropenia181. Varying doses and duration of G-CSF was noted within this 
study which did not confirm any improvement in pregnancy outcomes. There 
was 50% incidence of miscarriages in women who received G-CSF and those 
who didn’t receive G-CSF. 
 
Discussion 
Immune mediated treatment failure in IVF and immune mediated miscarriages 
can cause significant dilemma and frustration to patients and clinicians alike. 
Many studies from early 2000s suggest and support use of G-CSF for these 
conditions. There is evidence to suggest increase in implantation rates for 
women undergoing ART and a decrease in incidence of miscarriages in women 
with recurrent miscarriages.   
 
The exact mechanisms involved in improving pregnancy outcomes are 
unknown. Animal and human studies suggest G-CSF improves oocyte quality 
and maturation, endometrial thickness, endometrial receptivity and live birth 
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rates.  Animal studies involving rats suggest anti-abortive actions of G-CSF; 
however, another study in rabbits did not confirm this182,183.  
 
G-CSF administration appears to be associated with an increase in regulatory T 
cells and dendritic cells and appears to influence endometrial expression of 
genes crucial for the implantation process. The increase in the cytokines and 
genes may result in endometrial vascular remodelling and immune-modulation 
by altering the cellular adhesion pathways185,186. 
 
This review incorporated a comprehensive literature search using electronic 
databases. All relevant citations were included and hand search of bibliography 
was also conducted. I also included data for pregnant women using G-CSF 
from population registry for other indications. (These data were not included in 
other available reviews till date).  
 
The major weakness of this review was the relatively low number of controlled 
clinical studies. Unlike other immunomodulatory treatment options, evidence 
for G-CSF is relatively new and therefore considered to be a novel option. 
Therefore the studies available had relatively small number of participants.  
This makes the conclusions less reliable.   
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There was a high level of heterogeneity among the studies with different 
indications for use of G-CSF, different treatment methods and varying doses. 
Studies conducted by Gleicher et al172. , Eftekhar et al.167 , Kunicki et al.143 , Lee et 
al.173 and  Xu et al177 had low participant number.  Most of the studies used a 
methodology of intrauterine infusion of G-CSF as a single dose or a maximum 
of 2 doses.  
 
Zeyneloglu et al. suggested dual administration of G-CSF is more effective178; 
however, there is no clear evidence for such approach. Majority of studies had 
no control groups and/or control groups in some studies were not clear (Wurfel 
et al.184).  
 
Out of the 17 studies identified here, only five were randomised studies. There 
was evidence of selection bias in studies conducted by Scarpellini et al.73 , Barad 
et al.169, Lee  et al.173, and Xu et al177.  
 
A meta-analysis was not performed for the following reasons: 
a. There was considerable difference in the dosage and timing of medications in 
each study.  
b. There were no controls or else, the controls did not receive any medications 
in most of the studies.  
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c. Ideally, effect of intervention should be assessed by RCT and there was no 
uniformity in the RCTs identified. 
d. Even though the population was matched in these studies, the interventions 
varied significantly. 
e. With low number of participants in most of the studies, the pooled estimate 
would have crossed null hypothesis which would have made it difficult to 
make a conclusion. 
f. Publication bias and lack of uniformity would have led to invalid and less 
meaningful interpretation of the literature.  
 
Even though this review provides supporting evidence, there was a clear need 
for further conclusive studies with proper methodology to evaluate efficacy of 
G-CSF. This warranted the need for a large multicentre RCT trial to answer this 
very important clinical question. 
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CHAPTER 4 
METHODS FOR A RANDOMISED, DOUBLE BLIND, MULTICENTRE, 
PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, 
SAFETY, AND TOLERABILITY OF RECOMBINANT HUMAN 
GRANULOCYTE COLONY STIMULATING FACTOR   IN PREGNANT 
WOMEN WITH A HISTORY OF UNEXPLAINED RECURRENT 
MISCARRIAGE 
 
Description of the study 
RESPONSE study was a randomised; double blind, multi-centre, placebo-
controlled study of subcutaneous Recombinant Granulocyte Colony 
Stimulating Factor (rhG-CSF) in pregnant women with a history of unexplained 
recurrent miscarriage. 150 women were randomised in a 1:1 ratio to receive 
subcutaneous rhG-CSF 130 mcg or placebo once daily (OD) for up to 9 weeks of 
treatment.  
During the screening period, participants underwent eligibility evaluation. 
Once eligibility was established, the participant began ovulation monitoring 
and attempts at spontaneous conception. The participant started a daily, 
pregnancy test with the first morning urine sample on the 6th day after 
ovulation or 5 days before the start of the next expected menstrual period 
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(whichever came  first). The test was continued until positive or until the onset 
of her next menstrual period.  
 
Once the home urine pregnancy test was positive, the participant immediately 
scheduled a visit to the study site for a repeat urine pregnancy test (the visit 
took place within 3 days of the positive home pregnancy test). A repeat urine 
pregnancy test was performed at the study site and if positive, the participant 
was randomised into the study and study drug treatment was initiated.  
 
For the purpose of the study, gestational age was calculated based on the 
ovulation date (Ovulation date was defined as the day after the ovulation test 
was reported to be positive). Weeks of gestation were calculated as ovulation 
date plus 2 weeks. At the time of randomisation, participants were between 3 to 
5 weeks of gestation. Participants who were determined to be at greater than 5 
weeks of gestation (i.e. greater than 3 weeks since the ovulation date) were not 
eligible for randomisation. Women who were unable to achieve a spontaneous 
pregnancy within 9 months of screening were discontinued from the study. 
 
Randomised participants started daily subcutaneous injections of rhG-CSF or 
placebo and underwent an ultrasound examination at 6 weeks gestation for 
assessment of clinical pregnancy. Women who had a clinical pregnancy 
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underwent repeat ultrasound examinations at Weeks 8, 12 and 20 of gestation. 
Study drug was not continued beyond 12 weeks of gestation, as total duration 
of treatment was up to 9 weeks from time of randomisation. Participants who 
were not found to be pregnant (miscarriage, biochemical pregnancy, PUL or 
ectopic pregnancy) were discontinued from the study and they entered a 4-
week post drug follow-up period. 
 
The primary outcome assessment (clinical pregnancy rate at Week 20 of 
gestation) was assessed via ultrasound examination. 
 
All participants were monitored for adverse events. All participants who 
received at least one dose of study drug were followed for safety for a 
minimum of 4 weeks following the last dose of study drug. Karyotype testing 
(where possible) was performed on products of conception as per protocol at 
the local recruiting site following a spontaneous pregnancy loss. Study team 
conducted telephone follow up assessments for women who maintained 
pregnancy through 20 weeks of gestation. This 8 weekly phone follow up 
assessed pregnancy status/outcomes and prescription medication use. One 
month following delivery, additional information were obtained, including 
pregnancy outcome, gestational age at delivery, mode of delivery, birth weight, 
and Apgar scores. 
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Rationale for study design 
In addition to its granulopoietic and stem cell mobilization effects, rhG-CSF has 
been demonstrated to have a well-documented immune-modulatory/immune-
regulatory effect in animals and humans. Multiple studies have shown that 
rhG-CSF can decrease T cell alloreactivity and inflammatory cytokine 
production186,187. Recombinant human granulocyte colony stimulating factor has 
also been demonstrated to increase regulatory T cell populations, with the net 
effect of induction of T cell tolerance without global immunosuppression188. The 
importance of inducing T cell tolerance in a normal pregnancy has been shown 
in studies conducted by Rowe at al and Samstein et al189,190.  These experimental 
models support the hypothesis that rhG-CSF treatment in infertility or recurrent 
pregnancy loss may have beneficial effects, as an imbalanced maternal immune 
response has been implicated in some types of unexplained infertility, recurrent 
implantation failure, and recurrent pregnancy loss, for e.g. the study by 
Fasouliotis et al191 . 
 
Williams et al based on his studies on tolerance induction in pregnancy 
observed that this hypothesis provided biological plausibility. He proposed that 
administration of G-CSF may reduce the rate of miscarriage192. Salmassi et. al193, 
McCracken et. al194, studied links between G-CSF and pregnancy by 
demonstrating expression of G-CSF and G-CSF receptors in pregnancy-
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associated tissues, including follicular fluid, endometrium, and placenta. 
Higher levels of both follicular as well as circulating endogenous G-CSF have 
been shown to correlate with improved pregnancy outcomes as evidenced by 
studies conducted by Salmassi et. al193 and Ledee et. al195. A single centre 
placebo controlled study using recombinant G-CSF demonstrated significant 
improvement in live birth in women who were diagnosed with unexplained 
recurrent miscarriage73.  A number of other small, single centre studies 
concluded the same biological and clinical effect. (Discussion of all these studies 
was conducted as part of a systematic narrative review ad explained in chapter 
3) 
 
Based on these previously published studies with rhG-CSF it was hypothesised 
that administration of rhG-CSF may have a beneficial effect in improving 
pregnancy outcomes in women with unexplained RPL.  
 
A phase 1, randomised, double-blind, placebo-controlled, dose-escalation study 
in 48 healthy female volunteers was completed prior to the RESPONSE study 
design. The phase 1 study consisted of 6 single- and multiple-dose cohorts with 
8 participants in each dose cohort, randomised in a 3:1 ratio to receive either 
rhG-CSF or placebo. rhG-CSF dose levels tested were 65, 130, and 260 mcg. 
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Overall, single and multiple SC doses of rhG-CSF up to 260 mcg appeared to be 
safe and generally well tolerated by the healthy female volunteers.  
There were no deaths, serious adverse events (SAEs), or participant 
discontinuations due to adverse events (AEs) in the phase 1 study. No AEs met 
the National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) v4.03 Grade 3 or higher criteria. As expected, transient 
neutrophilia and increases in white blood cell (WBC) counts were observed 
following both single and multiple doses. Vital signs and electrocardiograms 
remained unaffected following rhG-CSF administration. No anti-drug 
antibodies (ADAs) were detected in any participants. Changes in peripheral 
blood cell subsets were observed that are consistent with supporting a state of 
maternal-fetal immune tolerance. These changes included temporary induction 
of toleragenic cell subsets and decreased percentages of pro-inflammatory and 
cytotoxic cell subsets, without evidence of global immune changes or 
suppression. For example, overall CD4+ and CD8+ T cells were unchanged in 
all treatment groups. However, within the CD4 compartment, there was a 
selective induction of toleragenic CD4+ CD25+  positive regulatory T cells (Treg 
cells) and a decrease in pro-inflammatory CD4+ CXCR3+ Th1 cells. Within the 
CD8+ T cell compartment, there was a decrease in the cytotoxic mucosa-
associated invariant T cells (MAIT cells). There were also changes within the 
non-T cell subsets that were consistent with induction of a toleragenic state, 
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including an increase in toleragenic myeloid derived suppressor cells (MDSC) 
and a decrease in cytotoxic natural killer (NK) cells. The CD1c+ dendritic cell 
(DC) subset was also decreased; these “professional” antigen cells are 
considered to be the most potent inducers of cytotoxic CD8+ T cells in the 
immune system. (NORA Therapeutics, Phase 1 study)197 
 
The changes described above were observed in all multi-dose rhG-CSF groups, 
and were not seen in any placebo group. Furthermore, with the exception of the 
increase in MDSC cells, the changes were only seen in the rhG-CSF multi-dose 
groups and not in the single dose groups. The changes in cell subsets occurred 
during the period of drug administration, and the changes returned to baseline 
levels within 72 hours of rhG-CSF discontinuation. 
 
A Phase 2, randomised, double-blind, placebo-controlled parallel-dose study in 
156 women with a history of repeated in vitro fertilization failures was 
conducted at multiple investigative centres in the United States. There were no 
AEs of special interest as identified prospectively in the protocol and no 
subjects discontinued study drug due to an AE.  
 
The pharmacokinetics of rhG-CSF were determined following SC 
administration in the Phase 1 study. Apparent clearance of rhG-CSF increased 
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between Day 1 and Day 10 were likely due to the known stimulatory effect on 
neutrophils and the well-established clearance of G-CSF by neutrophils. The 
assay for rhG-CSF measured only free drug changes in the free fraction of 
bioavailable dose over time due to an increased pool of neutrophils. The 
terminal half-life of rhG-CSF after multiple doses was approximately 8 to 11 
hours. The pharmacokinetic results showed that there was no rhG-CSF 
accumulation with daily dosing and that exposure increased with dose, 
although not in an exact dose-proportional manner. These data supported daily 
SC injections of rhG-CSF. There was no immunogenicity to rhG-CSF found in 
the Phase 1 study. Treatment with rhG-CSF resulted in rapid onset of effect on 
neutrophils and rapid offset once dosing ceased. The rhG-CSF dose level being 
evaluated in this study was selected based on the results of the nonclinical and 
clinical studies, which support the use of 130 mcg SC daily for up to 8 weeks (±1 
week). 
 
Outcome measures 
 
Primary outcome measure 
The primary outcome measure was clinical pregnancy rate at Week 20 of 
gestation. 
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Secondary outcome measures 
The secondary outcome measures were as follows: 
1. Live birth 
2. Live birth beyond 34 weeks of gestation 
3. Clinical pregnancy at Weeks 6, 8 and 12 of gestation 
4. Spontaneous pregnancy loss under 24 weeks 
5. Stillbirth 
6. Neonatal birth weight 
7. Infants discharged alive from the hospital following delivery 
8. Maternal adverse events and serious adverse events during the treatment 
period and within 4 weeks of the last dose of study drug 
9. Changes in clinical laboratory parameters following study drug exposure 
10. Major congenital anomalies 
11. Diagnosis of pre-eclampsia, eclampsia, gestational hypertension, or placenta 
       accreta.  
12. Incidence of anti-drug antibody (ADA) formation 
 
Exploratory pharmaco-dynamic outcome measure 
The exploratory pharmaco-dynamic outcome measure was changes in levels of 
circulating white blood cell subsets. 
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Safety plan 
Safety was monitored through the assessment of adverse events, vital signs, 
physical examinations, and clinical laboratory parameters throughout the 
treatment period and 4-week post-drug follow-up period. 
In order to minimise unnecessary exposure, any participant receiving study 
drug who was no longer pregnant discontinued study drug. Following 
discontinuation, they were followed up for a minimum of 4 weeks after last 
dose of study drug. An external and independent Data Monitoring Committee 
(DMC) also followed up this study. The DMC facilitated close monitoring of 
safety data and serious adverse events. The DMC also reviewed all available 
safety data at pre-specified time points throughout the study and based on 
these safety reviews, the DMC made regular recommendations regarding the 
safe conduct of the study (including termination of dosing). 
 
 
Adverse events of special interest and study stopping rules 
None of the participants experienced any adverse events of special interest in 
this study. Therefore no participants had study discontinuation for this reason. 
The adverse events of special interest were : 
 2 participants receiving active study drug with splenic rupture 
 2 participants receiving active study drug with anaphylaxis 
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 2 participants receiving active study drug with acute respiratory distress 
syndrome (ARDS)  or acute lung injury (ALI) 
 2 participants receiving active study drug with major cardiovascular 
event 
Hyperleucocytosis 
In order to avoid potential complications of hyperleucocytosis within 
RESPONSE study, WBC counts were monitored closely throughout the 
treatment period. Full blood counts (FBC) were obtained at baseline and during 
the treatment period. No participants had a WBC count more than 70,000/μL 
(which was the cut-off) for study drug treatment suspension.  
 
Immunogenicity 
Immunogenicity is a potential adverse effect of any biologic therapy, and may 
be of particular concern if a neutralizing antibody response occurs against 
recombinant forms of endogenous proteins such as G-CSF. In theory, 
neutralizing antibodies to rhG-CSF may cross-react with endogenous G-CSF, 
which may manifest clinically as induction of a neutropenic state and increased 
infection risk. An additional risk exists in pregnancy due to the risk of trans-
placental passage of ADA and potential impact on the fetus. 
Therefore, an immunogenicity monitoring plan was put in place for RESPONSE 
study. All participants receiving study drug had serum specimens taken at 
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baseline, randomisation, 6th week, 12th week, 16th week or 4 week post drug 
follow up as appropriate. None of the participants developed anti-drug 
antibody within this study. 
 
Blinding and Minimisation of Bias 
RESPONSE study was a randomised, double-blinded, and placebo-controlled to 
minimise potential bias in treatment assignment, participant monitoring, and 
endpoint evaluations. 
 
All participants, investigative site study staff, and investigative site monitors 
were blinded to treatment assignment. In emergency situations such as an 
adverse event, the Investigator unblinded the participant’s treatment 
assignment immediately, or as quickly as possible. The investigators had 
unrestricted and immediate access to unblind the participant’s treatment 
assignment by accessing the Interactive Web Registration System (IWRS). 
Further, the Investigator followed-up the circumstances with the Medical 
Monitor. Additionally, WBC and WBC subset counts, alkaline phosphatase, uric 
acid, and lactate dehydrogenase (LDH) had the potential to unblind the 
investigators and site monitors. During the course of the study, only designated 
central laboratory staff, members of the DMC, and the Sponsor had access to 
these data. Routine pregnancy booking blood tests performed during the first 
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trimester typically included a WBC count as part of the full blood count (FBC). 
Physiological changes in WBC count as anticipated with rhG-CSF 
administration would have led to unnecessary confusion and study unblinding. 
In order to prevent these possible outcomes, participants and their general 
practitioners were provided with the results of the study FBC collected at the 
time of randomisation for use as a component of the booking blood tests. It was 
also requested not to include FBC as part of their booking blood tests. The DMC 
and sponsor were unblinded to treatment assignment and independently 
reviewed safety findings. 
 
MATERIALS AND METHODS 
Participants 
Females aged 18-37 years with a history of unexplained recurrent pregnancy 
loss. 
 
Inclusion criteria 
Participants had to meet the following criteria to be eligible for randomisation 
into the study: 
1. Pre-menopausal female 18-37 years of age at consent, trying to conceive. 
2. Documented history of unexplained recurrent pregnancy loss, defined as: 
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 Spontaneous loss of three or more pregnancies (non-consecutive) prior to 
20 completed weeks of gestation. 
 At least two of the losses must have involved intrauterine clinical 
pregnancies prior to 20 completed weeks of gestation with normal or 
unknown fetal karyotype. 
 Spontaneous conception, as confirmed by urine pregnancy test 
performed at the investigative site 
 Body mass index (BMI) of 19-35 kg/m2 at consent 
 
 
Exclusion criteria 
Participants who had any of the following criteria were excluded from 
randomisation into the study: 
1. Greater than 5 weeks of gestation (i.e. greater than 3 weeks from the 
ovulation date) when presenting for randomisation. Ovulation date was the day 
after the ovulation test is first positive. 
2. Known karyotype abnormalities in either the participant or her current male 
partner. 
3. Uncorrected clinically significant intrauterine abnormalities present at the 
time of consent (as assessed by ultrasound, hysterosonography, 
hysterosalpingography, or hysteroscopy within 3 years prior to consent). 
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4. Abnormal vaginal bleeding of unknown cause  
5. Current diagnosis of infertility in either the participant or her current male 
partner 
6. Current or past diagnosis of the following: 
(a) Systemic autoimmune disease (e.g. systemic lupus erythematosus, 
Hashimoto’s thyroiditis, Graves’ disease, rheumatoid arthritis), (b) 
Antiphospholipid syndrome or presence of lupus anticoagulant or 
anti-cardiolipin antibodies,  (c) Protein C or S deficiency, (d) Other 
thrombophilia or evidence of thrombophilia (e.g. recurrent deep vein 
thrombosis, pulmonary embolism),  (e) Hyperprolactinemia, (f) High 
risk of cervical incompetence in the investigator’s opinion (g) High-
grade cervical dysplasia with conisation/surgery  
7. Any uncontrolled clinically significant medical condition (e.g. asthma, type II 
diabetes, infection). 
8. The following laboratory abnormalities at initial consent and within 3 months 
prior to randomisation 
(a) Thrombocytopenia or thrombocytosis (platelet count < 75,000/μL or > 
500,000/μL), (b) Neutropenia or neutrophilia (absolute neutrophil 
count < 1500/μL or > 10,000/μL), (c) Leucopenia or leucocytosis (white 
blood cell count < 3000/μL or > 15,000/μL), (d) Creatinine, hepatic 
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transaminases, lactate dehydrogenase (LDH), alkaline phosphatase, 
or uric acid ≥ 1.5x upper limit of normal (ULN). 
9. Use of lithium within 1 month prior to consent. 
10. Known hypersensitivity to any rhG-CSF drug product, any of its 
components, or any E. coli-derived proteins. 
11. History of any of the following conditions:  
(a) Human immunodeficiency virus (HIV) infection, (b) Malignancy 
within the past 5 years other than treated basal cell carcinoma or 
squamous cell carcinoma of the skin, (c) Splenomegaly or splenic 
rupture, (d) Adult respiratory distress syndrome (ARDS), acute lung 
injury (ALI), or pulmonary oedema, (e) Sickle cell anaemia, (f) Acute 
myocardial infarction, stroke, or revascularization (coronary or 
cerebral). 
12. Previous rhG-CSF therapy for any indication. 
13. In the investigator’s opinion, any contraindication to the use of an 
investigational drug. (for e.g. anticipating poor compliance) 
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Method of treatment assignment 
Eligible participants were randomised to receive rhG-CSF 130 mcg or placebo in 
a 1:1 ratio. Stratified permuted block randomisation with number of prior 
miscarriages (3, >3), and age (<35, 35-37) as the stratification factors, were used. 
An Interactive Web Response System(IWRS) was used to perform the 
randomisation. 
 
Study drug 
 
Study drug supply, storage, and preparation 
Recombinant human granulocyte colony stimulating factor and placebo were 
supplied to the investigative site in glass 1 mL prefilled syringes. Each prefilled 
syringe contained 0.5 mL of a sterile, preservative-free, aqueous solution 
intended for single-use subcutaneous administration. The rhG-CSF 130 mcg 
formulation contained 260 mcg/mL of rhG-CSF in sodium acetate, D-sorbitol 
and polysorbate 80 at a pH of 4.0.  Placebo contained sodium acetate, D-sorbitol 
and polysorbate 80 at a pH of 4.0. Prefilled syringes were stored at 2-8ºC (36-
46ºF). Prefilled syringes were supplied in kits packaged with 8 syringes and 
plunger rods per kit. One kit was issued at a time via IWRS at randomisation 
and visits prior to the Week 6 visit (e.g. Week 4 and Week 5 visits, if applicable). 
Two kits were issued via IWRS at the Week 6, Week 8, and Week 10 visits. One 
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prefilled syringe was required for each subcutaneous injection. The 
investigative site personnel trained the participant on study drug 
administration prior to administration of the first dose according to the patient 
instructions. The first dose of study drug was administered at the investigative 
site. The participants themselves administered subsequent doses. Participants 
were instructed to administer this dose at approximately the same time each 
day (within 20 to 28 hours after the previous dose). 
 
Route of administration 
Each participant received rhG-CSF 130 mcg or placebo as a daily subcutaneous 
injection. The participants were instructed to rotate injections sites every day. 
 
Dosage Modification 
No dosage modification was allowed in this study. 
 
Study Drug Suspension 
There were no study suspension due to any adverse events.(Overall, there were 
5 participants who had study discontinuation for adverse events ; two 
participant in the rhG-CSF group and three participants in the placebo group, 
respectively).  
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Missed or Delayed Doses 
Each dose of study drug was administered once daily at approximately the 
same time each day (within 20 to 28 hours after the previous dose). If it had 
been longer than 28 hours after the previous dose, the dose was skipped, and 
the following dose was administered on the regular schedule. The skipped dose 
was considered and documented as a missed dose. 
 
Labelling and study drug accountability 
All prefilled syringes were labelled in kits containing eight prefilled syringes 
each. Study accountability was maintained for all prefilled syringes distributed 
to the study sites. Study kit also included an ice pack to be used in emergencies 
to comply with the temperature regulations.  
 
Concomitant therapies, excluded therapies and clinical practice 
 
Concomitant therapies 
Concomitant therapy included any prescription medications or over-the-
counter preparations used by a participant between randomisation through the 
4-week post drug follow-up visit. A record of all concomitant medications 
received by participants during the treatment period and within 4 weeks of the 
last dose of study drug was maintained during the study for each participant. A 
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record of all prescription medications was maintained for participants until live 
birth (for women who remained pregnant) or as appropriate (for participants 
with other outcomes). 
 
Participants who had well-controlled chronic diseases was allowed to continue 
with stables doses of medications. Participants who had adverse events were 
allowed to have appropriate interventions to treat the adverse events. A 
detailed description of the type of the drug, treatment period, dosing regimen, 
the route of administration and drug indication was maintained.  
 
Excluded therapies 
Excluded therapies from consent through the 4-week post drug follow-up visit, 
unless otherwise specified, included the following: 
 Progesterone 
 Low molecular weight heparin (LMWH) 
 Immunomodulatory agents such as systemic corticosteroids, TNF-
inhibitors, or intravenous immunoglobulin (IVIG) 
 Stable doses of inhaled or intranasal corticosteroids were not excluded 
 Use of lithium (beginning within 1 month prior to consent) 
 Medications known to have harmful effects in pregnancy, unless 
medically indicated 
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 Any other investigational therapies. 
 Use of non-standard prescription medications for “pregnancy support” 
of recurrent pregnancy loss will be excluded unless medically indicated 
for other conditions. Examples of such therapies include progesterone, 
intravenous immunoglobulin (IVIG), LMWH, and tumour necrosis 
factor (TNF) inhibitors.  
 
Details of Study Assessments 
 
See table 4.1.  for a detailed schedule of events. The following participant flow 
diagram provides a summary of assessments and decision points for each 
participant. 
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                                                                Figure 4.1 – Participant flow in the study 
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Table 4.1 - Schedule of Events 
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Abbreviations: ADA = antidrug antibodies; exam = examination; F/U = follow 
up; PD = pharmaco-dynamic; Tx = treatment.  
Note: Randomisation visit to occur 0 to 3 days after positive home pregnancy 
test  
 
a.  Week 4 visit did not occur for participants randomised ≥4 weeks of 
gestation; Week 5 visit did not occur for participants randomised at 5 
weeks of gestation.  
b. The 4-week post drug Follow-up visit was only for participants who 
either discontinued study drug prior to Week 12 or who did not have a 
clinical pregnancy at Week 12.  
c. After first dose, participant was observed ≥1 hour. All subsequent doses 
could be administered outside the clinical site. Participants were to 
administer study drug as close to the same time each day as possible (20 
to 28 hours after previous dose).  
d. During screening, haematology and chemistry samples were collected 
every 3 months (±1 week) in participants who have been unable to 
achieve pregnancy.  
e. Lupus anticoagulant was not required if the participant had a negative 
test result within 5 years prior to consent; proteins C and S were not 
required if the participant had a negative test result at any time in the 
past.  
f. Additional ADA assessments were conducted in participants who 
seroconvert periodically until antibody levels return to baseline through 
the end of the study.  
g. At Week 6, 8, and 12 of gestation, the ultrasound visit window was ±3 
days. Included delivery information and diagnosis of pre-eclampsia, 
eclampsia, gestational hypertension, or placenta accreta.  
h. After informed consent, but prior to study drug administration, only 
SAEs caused by a protocol-mandated intervention were collected.  
i. Included delivery information and diagnosis of preeclampsia, eclampsia, 
gestational hypertension, or placenta accreta.  
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Ovulation monitoring 
Ovulation monitoring was performed by the participants during the screening 
period using a standardised commercially available ovulation monitoring kit. 
The date of ovulation during each menstrual cycle was recorded in the 
participant diary. Ovulation date was defined as the day after the ovulation test 
was first positive. The study staff helped participants to estimate the ovulation 
date if they had unreliable ovulation tests or for participants who had 
polycystic ovaries. 
 
Urine pregnancy test 
Participants started daily home urine pregnancy tests using a standardised 
commercially available home pregnancy test starting 6th day after ovulation or 
5 days before the start of the next expected menstrual period (whichever came 
first). A urine pregnancy test at the investigative site was assessed to determine 
pregnancy status at the initial screening visit. Following a positive home urine 
pregnancy test, a repeat urine pregnancy test was performed at the time of 
randomisation. 
 
Physical examinations 
Physical examinations were performed at various time points. A detailed 
physical examination was performed at the initial screening visit, at the 
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randomisation visit, at 8th week of gestation, and 4 weeks after the last dose of 
study drug. Abnormalities identified as pre-existing before randomisation was 
recorded in the medical history. Clinically significant abnormalities that 
appeared after randomisation were recorded as adverse events. Height was 
recorded at screening visit and weight was recorded at all physical 
examinations. 
 
Vital signs 
Vital signs (including blood pressure, respiration rate, heart rate, and oral or 
tympanic temperature) was obtained at all study visits with the exception of 
follow-up phone visits and live birth visit. Blood pressure and heart rate was 
measured after sitting or supine for a minimum of five minutes. 
 
Laboratory evaluations 
Clinical laboratory evaluations of blood samples, including biochemistry panel 
and haematology, were conducted as per study schedule. Screening included 
evaluation of additional parameters in the collected blood samples to facilitate 
eligibility evaluation. All bloods were analysed at an external laboratory to 
maintain uniformity in laboratory assessments. 
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Ultrasound 
Ultrasound scan was performed at weeks 6, 8, 12, and 20 of gestation to assess 
and confirm clinical pregnancy  
 
Telephone Follow-up Visits 
Investigative site staff contacted participants via telephone every 8 weeks (±3 
days) during pregnancy, starting at Week 24 (±3 days) of gestation, to assess 
pregnancy outcomes and to record prescription medication use. 
 
Live Birth Visit 
One month following delivery, additional information was obtained, including 
pregnancy outcome, diagnosis of pre-eclampsia, eclampsia, gestational 
hypertension, or placenta accreta, gestational age at delivery, mode of delivery, 
birth weight, and Apgar scores. 
 
Additional Visits 
If any participant needed extra visits as part of assessment for AE or SAE or for 
any other reason (for e.g. collecting extra medications) the additional visit was 
logged as an extra visit linked to the nearest gestation.   
 
 
111 
 
Participant Discontinuation 
Participants could withdraw from treatment or from participation in study 
visits, or withdraw consent from the study at any time. Participants who 
decided to withdraw from treatment and those who were not pregnant 
completed the 4-week post drug follow-up visit.  
 
Early Discontinuation of Study Drug 
Participants were allowed to discontinue study drug under any of the following 
circumstances: 
 The participant wished to discontinue study drug treatment for any 
reason 
 The presence of any medical condition that the investigator determined 
which may jeopardise the participant’s safety if she continued with study 
drug treatment 
 Noncompliance (e.g., missed doses, visits) 
 Determination by the investigator that discontinuation was in the best 
interest of the participant 
 
For participants who withdrew from study visits, every attempt was made  
a. to have them complete the 4-week post-drug follow-up visit prior to 
withdrawal from participation, or  
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b. to contact them for follow-up information through their pregnancy 
outcome, as applicable.  
 
If the participation was withdrawn for reasons related to an AE, every effort 
was made to follow the participant until resolution of the event. The reason for 
premature discontinuation of treatment for participants was recorded on the 
eCRF.  
 
Replacement of Withdrawn Participants 
Participants who discontinued study drug or discontinue from the study 
following randomisation were not replaced by new participants. 
 
ASSESSMENT OF EFFICACY AND PHARMACODYNAMICS 
 
Efficacy assessments 
Clinical pregnancy was defined as evidence of at least one intrauterine fetus or 
gestational sac with heartbeat on obstetric ultrasound. The primary outcome of 
the study was clinical pregnancy rate at or beyond 20 weeks of gestation. Live 
birth was defined as delivery of one or more infants with any signs of life, and 
was reported at each participant’s delivery. Live birth rate was used as a 
secondary efficacy assessment. 
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ASSESSMENT OF SAFETY 
Safety assessments consisted of  
 monitoring and recording protocol-defined adverse events (AEs) and 
serious adverse events (SAEs) 
 measurement of protocol specified laboratory variables and  
 measurement of protocol-specified vital signs 
 
Safety parameters and definitions 
 
Spontaneous pregnancy loss 
Spontaneous pregnancy loss was defined as the spontaneous loss of a 
pregnancy from the time of positive urine pregnancy test at randomisation until 
24 completed weeks of gestation. Spontaneous pregnancy losses were further 
categorised into  
 pre-clinical losses (i.e. prior to 6-week ultrasound assessment) and  
 clinical losses (i.e. following 6-week ultrasound assessment). 
 
Stillbirth 
Stillbirth was defined as death before the complete expulsion or extraction of a 
product of fertilization from its mother, at or after 24 completed weeks of 
gestation. The death was indicated by the fact that, after such separation, the 
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fetus does not breathe or show any other evidence of life, such as heart beat, 
umbilical cord pulsation, or definite movement of voluntary muscles. 
 
Adverse event 
An adverse event (AE) was defined as any event, side effect, or other untoward 
medical occurrence that occurs in conjunction with the use of a medicinal 
product in humans, whether or not it is considered to have a causal relationship 
to the use of the medicinal product. An AE can, therefore, be any unfavourable 
or unintended sign (this could include a clinically significant abnormal 
laboratory finding), symptom, or disease temporally associated with the use of 
a medicinal product. All AEs, whether volunteered, elicited, or noted on 
physical examination, were recorded from first study drug administration until 
the 4-week study drug follow-up visit. Pregnant participants who had a Week 
16 visit instead of a 4-week study drug follow-up visit had AEs recorded from 
first study drug administration until the Week 16 visit. 
An AE included a/an: 
 exacerbation of a pre-existing illness 
 increase in frequency or intensity of a pre-existing episodic event or 
condition 
 condition detected or diagnosed even though it may have been present 
prior to the start of the study 
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Serious adverse event 
A  SAE was any AE occurring that results in any of the following outcomes: 
 Death 
 Life-threatening situation (participant is at immediate risk of death) 
 Inpatient hospitalization or prolongation of existing hospitalization 
 Persistent or significant disability/incapacity 
 Congenital anomaly/birth defect in the offspring of a participant who 
received study drug 
 Significant medical event as judged by the investigator (e.g., may 
jeopardise the participant or may require medical/surgical intervention 
to prevent one of the outcomes listed above) 
 
Clinical laboratory abnormality and other abnormal assessment as AE and 
SAE 
Abnormal laboratory findings (e.g. clinical chemistry, haematology, urinalysis) 
or other abnormal assessments (e.g. vital signs) were not reported as AEs. 
However, abnormal findings that are deemed clinically significant (i.e. 
requiring medical or surgical intervention) or are associated with signs and/or 
symptoms were recorded as AEs (if they met the definition of an AE). Clinically 
significant abnormal laboratory or other abnormal findings that were present 
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prior to study drug administration and worsened after study drug 
administration were also included as AEs (and SAEs, if serious).  
 
Major congenital anomaly 
Major congenital anomalies were defined as per the Metropolitan Atlanta 
Congenital Defects Program (MACDP) [MACDP 2007].A major congenital 
anomaly was defined as a significant deviation from normal that is present at or 
before birth. Major anomalies were those which required medical or surgical 
treatment, or which had significant cosmetic, health, or developmental 
consequences.  Investigators also reported any isolated anomalies, multiple 
malformation syndromes, identifiable genetic/inborn conditions or any 
structural anomalies.  All pregnancy outcomes will be reviewed for diagnosis of 
major congenital anomalies –  including live births , stillbirths, spontaneous 
pregnancy losses, and elective abortions.  
 
Maternal obstetric events 
Maternal obstetric events like pre-eclampsia, eclampsia, gestational 
hypertension, placenta accrete were also recorded. 
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Assessment of adverse event severity 
AE severity (apply event-specific NCI CTCAE grading criteria) scale was 
defined as: 
1.  Mild - Transient or mild discomfort ( lasting up to 48 hours); no 
interference with the patient’s daily activities; no medical 
intervention/therapy required 
2. Moderate - Mild to moderate interference with the patient’s daily 
activities; no or minimal medical intervention/ therapy required 
3. Severe - Considerable interference with the patient’s daily activities; 
medical intervention/therapy required; hospitalization possible 
4. Very severe, life threatening, or disabling  - Extreme limitation in 
activity; significant medical intervention/ therapy required, 
hospitalization probable 
5. Death related to AE 
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Assessment of adverse event causality/relatedness 
The investigator’s assessment of study drug relatedness on the AE form of the 
eCRF (or the SAE form if applicable) was based on the following causality: 
 Likely Related: A reaction that followed a reasonable temporal sequence 
from administration of the study drug; that followed a known or 
expected response pattern to the suspected study drug; or for which 
other potential aetiologies were considered less likely factors than the 
study drug. 
 Likely Unrelated: A reaction that, considering all potential aetiologies, 
was most likely due to factors, other than the study drug. 
All investigators was requested to include a rationale for the causal relationship 
in the site documents which was also supported by relevant laboratory tests, 
histopathology evaluations, and the results of other diagnostic procedures.  
 
Adverse event reporting period 
Any AE that occurred during the study was recorded on study site source 
documentation. Adverse events and serious adverse events (SAEs) were 
recorded from the first study drug administration through the 4-week post 
drug follow-up visit (or the Week 16 visit for pregnant participants who have a 
Week 16 visit instead of a 4-week study drug follow-up visit). After informed 
consent (but prior to initiation of study drug administration) only SAEs caused 
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by a protocol-mandated intervention were  collected (e.g., SAEs related to 
invasive procedures such as blood collection). It was the investigators duty to 
attempt to establish a diagnosis of the event based on the signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis was 
documented as the AE (and SAE if serious) and not the individual 
signs/symptoms. If a clinically significant abnormal laboratory finding or other 
abnormal assessment meets the definition of an AE, then the AE form of the e-
CRF had to be completed. The diagnosis, if known, was recorded as the AE 
rather than the abnormal finding or assessment. 
 
Follow-up of AEs and SAEs 
All attempts were made to follow up AE and SAE s regardless of attribution 
until resolved, judged stable and unlikely to resolve or until the 4-week post 
drug follow-up visit. Pregnant participants who had a Week 16 visit instead of a 
4-week study drug follow-up visit had AEs followed up until the Week 16 visit.  
The investigator was responsible for ensuring that AE and SAE follow-up 
included any supplemental investigations as may be indicated to elucidate as 
completely as practical the nature and/or cause of the AE or SAE.  
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Reporting SAEs to Institutional Review Board (IRB), Independent Ethics 
Committee (IEC) and Data Monitoring committee  
All investigators submitted notification of any AE or SAE s to the CRO within 
24 hours. Any SAE related to study participation (e.g. procedures), which 
occurred before the study drug administration (but after consent), were also 
promptly reported to the Sponsor.  
 
DATA ANALYSIS METHODS 
Analysis was primarily descriptive in nature with the endpoints summarised 
by treatment group and visit. For continuous variables, the following 
information was presented: n, mean, standard deviation, median, minimum 
and maximum. These statistics were presented using the actual value at 
baseline and the change from baseline for later data. Baseline will be the last 
observation prior to treatment. For categorical variables counts and percentages 
were used. 
 
Sample Size and Decision Rule 
The alpha level used will be a one-sided alpha level of 10%. The target sample 
size was 150 randomised and treated participants. Participants was randomised 
in a 1:1 ratio. This sample size was selected to achieve >90% power when the 
clinical pregnancy rates are 60% for placebo and 80% for rhG-CSF . The sample 
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size calculations were performed in PASS 2008 and utilised a Chi Squared test. 
The primary analysis was a CMH test controlling for the stratification factors.  
 
Handling of missing data 
For summary statistics missing data were not imputed; results were reported 
based upon observed data except for missing or partial dates and the clinical 
pregnancy rate at Week 20 of gestation endpoint (primary outcome). If 
determination of treatment period (on treatment, pre-treatment, post treatment) 
was required but the corresponding date was missing or partial, then the event 
was considered to be within treatment (unless the portions of the date that are 
available indicate this is not possible). If pregnancy status at 20 weeks of 
gestation was not known, it was assumed that the participant was no longer 
pregnant (unless the subject is later found to be pregnant) 
 
Analysis populations 
Efficacy analysis were  based upon an intent-to-treat philosophy. The primary 
efficacy population was Full Analysis Set (FAS) that included all randomised 
and treated participants. Participants was analysed within the treatment group 
to which they were randomised. The primary safety population were all treated 
(placebo or rhG-CSF) participants. For safety analysis, participants were 
classified based upon the treatment received. Participant flow was monitored 
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by CRO and the sponsor and accounting of all randomised participants were 
performed. Participants who discontinued the study drug prematurely or 
withdrew from the study were summarised and listed, with the description of 
the reason for early termination/withdrawal. 
 
Participant characteristics 
Demographic and other baseline characteristics are listed and summarised in 
chapter 4 
 
Treatment Compliance and Extent of Exposure 
Participant compliance with study drug dosing was accessed via a site review 
of the returned syringes and the compliance record maintained by the 
participant. From these results, summaries of treatment compliance and 
exposure were produced. 
 
Efficacy Analysis 
The difference in the primary efficacy outcome measure (clinical pregnancy at 
20 weeks gestation) between rhG-CSF and placebo was tested using a CMH test 
controlling for the stratification factors (# of prior miscarriages (3, >3), age (<35, 
35-37)). The hypotheses being tested were: 
H0:PPlacebo ≥ PNT-100 Ha:PPlacebo < PNT-100 
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where PPlacebo is the placebo rate and PNBT-100 is the similar rate for the rhG-
CSF treatment arm. The results from this test will be compared to a 10% one-
sided alpha. This alpha level provides 90% likelihood of a correct positive 
assessment. Descriptive statistics were used to summarise the secondary 
endpoints. 
 
Safety analysis 
 
Adverse events 
The incidence of all AEs and treatment-related AEs were tabulated by treatment 
received. These AEs were classified by system organ class and preferred term 
using the Medical Dictionary for Regulatory Activities (MedDRA).If a 
participant reported more than one AE that was coded to the same system 
organ class or preferred term, the participant was counted only once for that 
specific system organ class or preferred term. Summaries of adverse events 
included event rates for each treatment arm. SAEs will be listed and 
summarised in a similar manner to AEs. 
 
Clinical safety laboratory results 
Clinical safety laboratory values were measured by a central laboratory. 
Summary statistics for actual values and for changes from baseline was 
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tabulated for laboratory results by scheduled visit. Graphs of laboratory values 
over time were produced. Shifts from baseline laboratory values was  tabulated 
and summarised.  
 
Vital signs 
The observed data and change from baseline for each measurement day was 
summarised with descriptive statistics. 
 
Interim analysis 
This study included a DMC that reviewed study results to identify potential 
safety concerns.  
 
ADMINISTRATIVE ASPECTS 
 
Changes to the protocol 
Protocol amendments was made only with the prior written approval of the  
Sponsor, investigator, and the IRB/REC. Protocol changes within RESPONSE 
study is listed in the appendix. 
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Monitoring and auditing procedures 
A clinical research organisation was designated for the monitoring the conduct 
of this study. The study site and investigators had assessments at regular 
intervals as part of monitoring by the CRO. 
 
Informed consent 
The purpose of the study, the procedures to be carried out, and any potential 
risks of study participation was described to the participants in non-technical 
terms in the participant information sheet (PIS). A copy of the PIS is attached in 
appendix. After reviewing and understanding the PIS, participants read, 
signed, and dated an IRB/IEC and Sponsor approved consent form before any 
study-specific procedures were carried out. Participants were assured that they 
could withdraw from the study at any time without jeopardizing medical care 
related to or required as a result of study participation. The original signed 
consent form was maintained in the investigator site file. Copy of the signed 
consent form was maintained in the participant’s medical records and provided 
to the participant. 
 
Communication with the IRB/IEC 
The protocol, informed consent form, other written participant information, and 
any proposed advertising material was submitted to the IRB/EC for written 
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approval. IRB/IEC approval of these documents and any changes was provided 
to the site staff through the investigator. All protocol amendments as 
mentioned above were also submitted to the IRB/IEC.  
 
Records and e CRFs 
All study data except central laboratory and immunogenicity data were 
recorded in an e CRF system. Data was entered at the site by trained site staff.  
All source documents from which e-CRF entries were derived was placed in the 
participant’s medical records. E-CRF was completed for every participant 
screened into the study. The study monitor (CRO) reviewed all e-CRFs in detail 
and had access to participant medical records, laboratory data, and other source 
documentation to allow all e-CRF fields to be verified by source data. Data 
consistency and plausibility checks against data entered into the e-CRF were 
included in the e-CRF system. For each instance of data modification, the 
system required a reason for change. The system kept a full audit trail of the 
data values, date and time of modification, and the electronic signature of the 
user who performed the change. The investigator finally signed and approved 
the participant’s e CRF following a full review of the e-CRFs. All essential 
documents, source data, clinical records, and laboratory data are retained by the 
clinical site in accordance with ICH E6 and the site’s data retention policies.  
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CHAPTER 5 
RESULTS FOR A RANDOMISED, DOUBLE BLIND, MULTICENTRE, 
PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, 
SAFETY, AND TOLERABILITY OF RECOMBINANT HUMAN 
GRANULOCYTE COLONY STIMULATING FACTOR   IN PREGNANT 
WOMEN WITH A HISTORY OF UNEXPLAINED RECURRENT 
MISCARRIAGES 
 
Patient flow through the trial  
Fig 5.1 and Table 5.1 represents the flow of participants and the study 
disposition through the study. 
 
A total of 340 women were screened into the study from 21 centres across the 
UK. Of these, 190 women were screen failures. (Reasons included those who 
failed to conceive within 9 months after screening, those women who had 
positive screening for thrombophilia or met exclusion criteria after initial 
screening tests or those who had change in medical status or change in personal 
circumstances). 
 
150 women were randomised to RESPONSE study,  of which 76 were assigned 
to rhG-CSF and 74 were assigned to placebo. 92/150 women (61.3%) completed 
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treatment and 58/150 (38.7%) discontinued early mainly due to loss of 
pregnancy between randomisation and 12th week of gestation (50/150 subjects 
[33.3%]). Overall, 140/150 women (93.3%) completed the study and 10/150 
women (6.7%) discontinued the study prematurely for reasons including loss to 
follow up, withdrawal of consent, and other reasons (for e.g. use of any 
excluded therapy or a decision made by study staff to adhere to study 
protocol).  
 
The participant flow in the study was broadly similar across the 2 groups. 44/76 
subjects [57.9%] completed treatment in rhG-CSF group compared to 48/74 
subjects [64.9%] in the placebo group. Loss of pregnancy between 
randomisation and Week 12 of gestation was generally similar in the 2 
treatment groups (27/76 subjects [35.5%] and 23/74 subjects [31.1%] in rhG-CSF 
and placebo groups, respectively). All women were followed up through the 
study, until live birth of the offspring/s or as appropriate. All participants were 
included in efficacy and safety analysis. 
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       Table 5.1 -  Flow of participants within RESPONSE Study 
 
rhG-CSF 
N=76 
n (%) 
Placebo 
N=74 
n (%) 
Total 
N=150 
n (%) 
Received Study Drug 76 (100.0) 74 (100.0) 150 (100.0) 
Completed Treatment 44 (57.9) 48 (64.9) 92 (61.3) 
Early Discontinuation of Treatment 32 (42.1) 26 (35.1) 58 (38.7) 
Loss Of Pregnancy Between Randomisation And Week 12 Gestation 27 (35.5) 23 (31.1) 50 (33.3) 
Other Reasons 5 (6.6) 3 (4.1) 8 (5.3) 
Noncompliance 1 1 2 
Adverse Event 2 0 2 
Investigator Decision 0 1 1 
Participant Withdrew Consent 2 1 3 
Completed Study 72 (94.7) 68 (91.9) 140 (93.3) 
Premature study discontinuation 4 (5.3) 6 (8.1) 10 (6.7) 
Lost To Follow Up 2 (2.6) 5 (6.8) 7 (4.7) 
Participant Withdrew Consent 1 (1.3) 0 1 (0.7) 
Other 1 (1.3) 1 (1.4) 2 (1.3) 
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Figure 5.1 - Enrolment, Randomisation, Follow up and Analysis 
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Baseline characteristics 
The baseline characteristics of the participants are shown in table 5.2 and table 
5.3 
 
Age 
Most women (122 [81.3%]) were under the age of 35 yrs.  within the study. 
Mean age (SD) was 31.1(3.60) in rhG-CSF group and 29.9(4.69) in the placebo 
group, respectively.  
62 women (81.6%) were under the age of 35 and 14 women (18.4) were or over 
the age of 35 in the rhG-CSF group. 60 women (81.1%) were under the age of 35 
and 14 women (18.9) were or over the age of 35 in the placebo group. 
 
Ethnicity 
Most women (134[89.3%]) were from the white ethnicity with the study. In the 
rhG-CSF group, 71(93.4%) were white, 3(3.9) were of Asian Pakistani ethnicity, 
1(1.3%) from other Asian origin and 1(1.3%) from mixed race origin 
respectively. In the placebo group, 63(85.1%) were white, 4(5.4%) were of mixed 
ethnicity, 2(2.7%) were from Asian Indian ethnicity, 2(2.7%) were from Chinese 
ethnicity, 1(1.4%) was from Asian Pakistani origin, 1(1.4) was from black British 
origin and 1(1.3%) from other black ethnic origin respectively.  
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BMI 
Most women were slightly overweight within the study. Mean BMI (SD) was 
26.31(4.19) in rhG-CSF group and 25.80(4.28) in the placebo group, respectively.  
Both the groups were generally balanced relative to age, ethnicity and BMI. 
 
Gestational age at start of treatment 
In the rhG-CSF group, 30 women (39.5%) were randomised between three and 
four weeks of gestation, 42 women (55.3%) were randomised between four and 
five weeks of gestation and 4 women (5.3%) were randomised at 5 weeks of 
gestation. In the placebo group, 33 women (44.6%) were randomised between 
three and four weeks of gestation, 35 women (47.3%) were randomised between 
four and five weeks of gestation and 6 women (8.1%) were randomised at 5 
weeks of gestation. 
 
Primary or secondary miscarriage 
In the rhG-CSF group, 38 women (50%) had primary RM and secondary RM 
respectively. In the placebo group, 37 women (50%) had primary RM and 
secondary RM respectively. 
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History of late miscarriages 
Within the study a total of 23 women had previous miscarriages after 12 weeks 
of gestation of which 13 (17.1%) were in the rhG-CSF group and 10(13.5%) were 
in the placebo group. 
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rhG-CSF 
N=76 
Placebo 
N=74 
Total 
N=150 
 Age (yrs) 
n 76 74 150 
Mean (SD) 31.1 (3.60) 29.9 (4.69) 30.6 (4.20) 
Median 32.0 31.0 31.0 
Min, Max 22, 37 21, 37 21, 37 
 Age Category - n (%) 
< 35 yrs 62 (81.6) 60 (81.1) 122 (81.3) 
>= 35 yrs 14 (18.4) 14 (18.9) 28 (18.7) 
 Race (UK)  –  n (%)                                                                                                                                                                                                                                     
Black British 0 1 (1.4) 1 (0.7) 
Chinese 0 2 (2.7) 2 (1.3) 
Indian 0 2 (2.7) 2 (1.3) 
Mixed Race 1 (1.3) 4 (5.4) 5 (3.3) 
Other Asian 1 (1.3) 0 1 (0.7) 
Other Black 0 1 (1.4) 1 (0.7) 
Pakistani 3 (3.9) 1 (1.4) 4 (2.7) 
White 71 (93.4) 63 (85.1) 134 (89.3) 
Table  5.2  – Demographics of study population  
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rhG-CSF 
N=76 
Placebo 
N=74 
Total 
N=150 
 Baseline Height (cm) 
n 76 74 150 
Mean (SD) 165.09 (7.447) 164.77 (7.374) 164.93 (7.388) 
Median 165.00 165.55 165.00 
Min, Max 147.5, 185.0 145.0, 178.0 145.0, 185.0 
    
  Baseline Weight (Kg)    
n 76 74 150 
Mean (SD) 71.74 (14.222) 70.30 (14.044) 71.03 (14.106) 
Median 70.25 67.25 69.00 
Min, Max 48.9, 117.7 47.4, 101.9 47.4, 117.7 
    
 Baseline BMI  (kg/m2) 
n 76 74 150 
Mean (SD) 26.31 (4.199) 25.80 (4.286) 26.06 (4.235) 
Median 26.10 24.80 25.85 
Min, Max 19.3, 35.1 19.4, 35.0 19.3, 35.1 
 
Table  5.2  – Demographics of study population  
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         Table 5.3 – Participant enrolment based on gestational age at start of treatment and previous miscarriages 
 
rhG-CSF 
N=76 
n (%) 
Placebo 
N=74 
n (%) 
Total 
N=150 
n (%) 
 
 Gestational Age at Treatment Start - n (%) 
<= 3 weeks 30 (39.5) 33 (44.6) 63 (42.0) 
4 weeks 42 (55.3) 35 (47.3) 77 (51.3) 
>= 5 weeks 4 (5.3) 6 (8.1) 10 (6.7) 
    
 Primary or Secondary Recurrent Miscarriage 
Primary 38 (50.0) 37 (50.0) 75 (50.0) 
Secondary 38 (50.0) 37 (50.0) 75 (50.0) 
    
 Prior Losses after Week 12 13 (17.1) 10(13.5) 23 (15.3) 
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Smoking status 
Smoking status of women and their partners is presented in Table 5.4.  
Overall, 27 women (18.0%) were current smokers, smoking a mean (SD) 
number of 6.4 cigarettes (4.50) per day. A total of 34 subjects (22.7%) had 
partners who smoked a mean (SD) number of 8.6 cigarettes (4.74) per day. 
Partners of women in the rhG-CSF group had a higher proportion of current 
smokers than the placebo group (19 partners [25.0%] and 15 partners [20.3%], 
respectively).  
The number of participants who smoked was broadly balanced in both groups. 
Alcohol consumption 
Alcohol consumption of women is presented in table 5.5. A total of 79 women 
(52.7%) in the study consumed alcohol; mean (SD) units of alcohol consumed 
per week was 3.5 units (3.27). In the rhG-CSF Group, 40 women (52.6%) 
consumed alcohol; mean (SD) units of alcohol consumed per week was 3.1 units 
(2.31). In the placebo group, 39 women (52.7%) consumed alcohol; mean (SD) 
units of alcohol consumed per week was 3.9 units (34.04). Alcohol consumption 
(by those who consumed) was balanced in both groups.  
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        Table 5.4 - Participant and Partner smoking status 
 
 
rhG-CSF 
N=76 
Placebo 
N=74 
Total 
N=150 
Current Smoker 14 (18.4) 13 (17.6) 27 (18.0) 
    
Cigarettes per day    
n 14 13 27 
Mean (SD) 6.4 (5.30) 6.5 (3.67) 6.4 (4.50) 
Median 5.0 6.0 5.0 
Min, Max 1, 20 1, 10 1, 20 
    
Partner Current Smoker 19 (25.0) 15 (20.3) 34 (22.7) 
    
Partner's Cigarettes per day    
n 19 15 34 
Mean (SD) 8.3 (5.14) 8.9 (4.32) 8.6 (4.74) 
Median 8.0 10.0 10.0 
Min, Max 1, 20 1, 20 1, 20 
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              Table 5.5 Participant alcohol intake  
 
 
rhG-CSF 
N=76 
Placebo 
N=74 
Total 
N=150 
 Alcohol Consumption 40 (52.6) 39 (52.7) 79 (52.7) 
 Alcohol Consumption per week (units)    
n 40 38 78 
Mean (SD) 3.1 (2.31) 3.9 (4.04) 3.5 (3.27) 
Median 2.0 2.0 2.0 
Min, Max 1, 10 1, 20 1, 20 
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Gynaecological history  
Table 5.6 provides a summary of the subjects’ gynaecologic history including 
gynaecological surgeries.  
 
23 women (15.3%) had a documented non-surgical gynaecological history 
including polycystic ovarian syndrome, fibroids, endometriosis, or intrauterine 
abnormalities. 11 women (14.5%) had a non-surgical gynaecological condition 
in the rhG-CSF group. 12 women (16.2) had a non-surgical gynaecological 
history in the placebo group.  
The gynaecological nonsurgical histories were generally balanced in both 
groups. The only exception was a slightly higher incidence of polycystic 
ovarian syndrome in the placebo group (6 women [8.1%] in the placebo group 
and 2 women [2.6%] in the rhG-CSF group respectively). 
 
Gynaecological surgery 
The past gynaecological surgical history for women included the following; 
evacuation of retained products of conception (ERPC) (78 women [52.0%]), 
other gynaecological surgical procedures (not otherwise specified [NOS]) (16 
women [10.7%]), large loop excision of transformation zone (10 women [6.7%]), 
and ovarian cystectomy (7 women [4.7%]). Gynaecological surgical history was 
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similar in both groups except a slightly higher history of LLETZ for women in 
the placebo group (8 women [10.8%] in the placebo group and 2 women [2.6%] 
in the rhG-CSF group respectively). 
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rhG-CSF 
n (%) 
Placebo 
n (%) 
Total 
n (%) 
 Prior Non-surgical Gynaecological History  11 (14.5) 12 (16.2) 23 (15.3) 
Polycystic Ovarian Syndrome 2 (2.6) 6 (8.1) 8 (5.3) 
Fibroids 5 (6.6) 3 (4.1) 8 (5.3) 
Endometriosis 4 (5.3) 2 (2.7) 6 (4.0) 
Intrauterine Abnormalities 2 (2.6) 5 (6.8) 7 (4.7) 
    
 Gynaecological Surgeries  46 (60.5) 44 (59.5) 90 (60.0) 
Large loop excision of transformation 
zone 
2 (2.6) 8 (10.8) 10 (6.7) 
Endometriosis surgery 2 (2.6) 0 (0) 2 (1.3) 
Tubal surgery 4 (5.3) 2 (2.7) 6 (4.0) 
Ovarian cystectomy 3 (3.9) 4 (5.4) 7 (4.7) 
ERPC 41 (53.9) 37 (50.0) 78 (52.0) 
Division of intrauterine adhesions 1 (1.3) 2 (2.7) 3 (2.0) 
Septum division 1 (1.3) 3 (4.1) 4 (2.7) 
Other Gynaecological Surgery 6 (7.9) 10 (13.5) 16 (10.7) 
    
 Other Gynaecological Disorders  4 (5.3) 4 (5.4) 8 (5.3) 
 
Table 5.6 – Participants previous gynaecological history 
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Reproductive history 
 
Table 5.7, table 5.8 and table 5.9 presents a summary of the reproductive 
histories of the study population.  
Women in the study had a mean (SD) of 5.1 previous pregnancies (2.21). The 
number of previous pregnancies ranged from three to sixteen. 37 (24.7%) had 3 
previous pregnancies, 40(26.7%) had 4 previous pregnancies, 29 (19.3%) had 5 
previous pregnancies and 44(29.3%) had more than 5 previous pregnancies 
respectively. A greater number of subjects in the rhG-CSF treatment group had 
a history of having had more than 5 pregnancies (25 subjects [32.9%]) compared 
with the placebo group (19 subjects [25.7%]). 
 
The mean (SD) gestational ages for births were similar in the 2 treatment groups 
(39.5 weeks [1.76] and 39.3 weeks [1.97] in the rhG-CSF and placebo groups, 
respectively). 
 
Women in the study had a mean (SD) of 4.3 previous preclinical and clinical 
losses (1.79). The number of previous clinical and preclinical losses ranged from 
three to fourteen losses. 70(46.7%) had 3 previous pregnancy losses, 36 (24.0%) 
had 4 previous pregnancy losses, 17(11.3%) had 5 previous pregnancy losses 
and 27 (18.0%) had more than 5 previous pregnancy losses respectively  
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More women in rhG-CSF group had a history of more than 5 previous 
spontaneous pregnancy losses (17 women [22.4%]) compared with the placebo 
group (10 subjects [13.5%]). There was a total of 647 pregnancy losses for 150 
women in the study and the mean (SD) gestational age at miscarriage was 7.8 
weeks (3.11) which were similar in both groups.  More subjects in the rhG-CSF 
group had experienced preclinical losses (42 women [55.3%]) compared with 
the placebo group (31 women [41.9%]). 
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       Table 5.7 - Participants previous pregnancy history  
 
rhG-CSF  
n (%) 
Placebo 
n (%) 
Total 
n (%) 
Previous Pregnancies 
   
n 76 74 150 
Mean (SD) 5.4 (2.51) 4.9 (1.83) 5.1 (2.21) 
Median 5.0 4.0 4.0 
Min, Max 3, 16 3, 10 3, 16 
3 previous pregnancies – n(%) 20 (26.3) 17 (23.0) 37 (24.7) 
4 previous pregnancies – n(%) 16 (21.1) 24 (32.4) 40 (26.7) 
5 previous pregnancies – n(%) 15 (19.7) 14 (18.9) 29 (19.3) 
>5 previous pregnancies – n(%) 25 (32.9) 19 (25.7) 44 (29.3) 
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Table 5.8 – Participants previous miscarriage history 
 rhG-CSF Placebo  
 
Total 
Previous spontaneous pregnancy losses  
(clinical and preclinical) 
n  76 74 150 
Mean (SD)  4.5 (2.11) 4.1 (1.35) 4.3 (1.79) 
Median  4.0 4.0 4.0 
Min, max  3, 14 3, 9 3, 14 
3 previous losses – n (%)  36 (47.4) 34 (45.9) 70 (46.7) 
>3 previous losses – n (%)  40 (52.6) 40 (54.1) 80 (53.3) 
4 previous losses – n (%)  16 (21.1) 20 (27.0) 36 (24.0) 
5 previous losses – n (%)  7 (9.2) 10 (13.5) 17 (11.3) 
>5 previous losses – n (%)  17 (22.4) 10 (13.5) 27 (18.0) 
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Table 5.9 – Participants previous pregnancy outcomes 
 rhG-CSF 
 
Placebo Total 
Prior pregnancy outcome - n (%)  
Spontaneous pregnancy loss (up to 20 weeks)  76 (100.0) 74 (100.0) 150 (100.0) 
Preclinical losses  42 (55.3) 31 (41.9) 73 (48.7) 
Clinical losses  76 (100.0) 74 (100.0) 150 (100.0) 
Elective abortion  9 (11.8) 6 (8.1) 15 (10.0) 
Still birth  0 (0) 2 (2.7) 2 (1.3) 
Live birth  38 (50.0) 37 (50.0) 75 (50.0) 
Other  3 (3.9) 1 (1.4) 4 (2.7) 
Prior pregnancies gestational age at birth 
n  51 49 100 
Mean (SD)  39.5 (1.76) 39.3 (1.97) 39.4 (1.86) 
Median  40.0 40.0 40.0 
Min, max  32, 42 34, 42 32, 42 
Prior pregnancies gestational age at loss 
n  343 304 647 
Mean (SD)  7.8 (2.69) 7.8 (3.53) 7.8 (3.11) 
Median  7.0 7.0 7.0 
Min, max  3, 22 4, 40 3, 40 
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Efficacy Results  
Table 5.10 summarise the primary and secondary outcomes in the study 
population and by treatment group.  
 
Primary Outcome 
Primary outcome of the study was clinical pregnancy at 20 weeks and beyond. 
The clinical pregnancy rates at 20 weeks of gestation was 59.2% (45/76) in the 
rhG-CSF group, compared with 64.9% (48/74) in the placebo group, giving a RR 
of 0.9 (95% CI: 0.7 to 1.2; p=0.48). 
 
Secondary Outcomes  
During the study, clinical pregnancies were confirmed by ultrasound scan at six 
weeks of gestation in 136 (90.7%) of the 150 randomised participants [67/76, 
88.2% in the rhG-CSF group vs 69/74, 93.2% in the placebo group, RR of 0.9 
(95% CI: 0.9 to 1.0; p=0.28)]. A further assessment of clinical pregnancies were 
conducted at 8 weeks which confirmed pregnancies in 110 randomised 
participants [51/76, 67.1% in the rhG-CSF group vs 59/74, 79.7%, RR of 0.8 (95% 
CI: 0.7to 1.0; p=0.09)]. Ongoing pregnancies were confirmed at approximately 
12 weeks in 96 (64.0%) of the women [45/76, 59.2% in the rhG-CSF group vs 
51/74, 68.9% in the placebo group, RR of 0.9 (95% CI: 0.7 to 1.1; p=0.224)].  
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The clinical pregnancy rates at 24 weeks of gestation was 59.2% (45/76) in the 
rhG-CSF group, compared with 64.9% (48/74) in the placebo group, giving a RR 
of 0.9 (95% CI: 0.7 to 1.2; p=0.48). Six women in the placebo group had live 
births at less than 34 weeks of gestation confirming clinical pregnancy rates at 
34 weeks of gestation at 59.2% (45/76) in the rhG-CSF group, compared with 
64.9% (48/74) in the placebo group, giving a RR of 0.9 (95% CI: 0.7 to 1.2; 
p=0.48). 5/45 (11.1%) women in the rhG-CSF group and 8/48 (16.7%) of women 
in the placebo group experienced preterm onset of labour (before 37 weeks and 
0 days of gestation), giving a RR of 0.7(95% CI: 0.3 to 2.0; p=0.54). There were no 
stillbirths in the study.  
 
One participant in the rhG-CSF group was diagnosed with an ectopic 
pregnancy. The number of spontaneous pregnancy losses up to 20 weeks was 
larger in subjects in the rhG-CSF group [28/76(36.8%) vs 25/74(33.8%) in the 
placebo group, giving a RR of 1.1 (95% CI: 0.7 to 1.7; p=0.70)]. Preclinical losses 
were the same in both treatment groups but there were more clinical losses in 
the rhG-CSF group compared with the placebo group [20/76(26.3%) vs 
17/74(23.0%) in the placebo group]. Amongst the 28 pregnancies that ended in 
miscarriage for participants receiving rhG-CSF, the median gestation was 6 
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weeks (IQR 6 to 7 weeks). Amongst the 25 pregnancies that ended in 
miscarriage for participants receiving placebo, the median gestation was 6.5 
weeks (IQR 6 to 9 weeks). The distributions of gestational age at live birth 
delivery for the rhG-CSF and placebo groups are given in Figure 5.2.   
 
The median birth weight was 3420.0 gm in the rhG-CSF group vs 3300.0 gm in 
the placebo group. All infants, both in the rhG-CSF and the placebo group were 
discharged alive from the hospital (46 infants in the rhG-CSF group vs 49 
infants in the placebo group). Neonatal congenital anomalies were observed in 
1/46 (2.1%) of babies in the rhG-CSF group versus 1/49 (2.0%) in the placebo 
group (RR of 0.9; 95% CI: 0.1 to 13.4; p=0.93).  
 
There was no incidence of antidrug antibody in the rhG-CSF group similar to 
findings in the phase 1 studies. 
 
There were no pregnancy losses in the time period from primary outcome to 
live birth; therefore, the live birth rate was 59.2% (45/76) in the rhG-CSF group, 
and 64.9% (48/74) in the placebo group, giving a relative risk of 0.9 (95% CI: 0.7 
to 1.2; p=0.48).  
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  Table 5.10 – Primary and secondary outcomes in RESPONSE study 
                                                                                                  rhG-CSF               Placebo              Relative Risk           P Value 
                                                                                                              no./total no. (%)                    (95%CI)                                                                                        
Outcome    
Pregnancy outcomes    
     Clinical pregnancy at 6 weeks                                                67/76(88.2)  69/74(93.2) 0.9 (0.9, 1.0) 0.28 
     Ongoing pregnancy at 8 weeks                                    51/76(67.1)  59/74(79.7) 0.8 (0.7, 1.0) 0.09 
     Ongoing pregnancy at 12 weeks                        45/76(59.2)  51/74(68.9) 0.9 (0.7, 1.1) 0.22 
     Live birth after 20 weeks of gestation    45/76(59.2)  48/74(64.9) 0.9 (0.7, 1.2) 0.48 
     Live birth after 24 weeks of gestation    45/76(59.2)  48/74(64.9) 0.9 (0.7, 1.2) 0.48 
     Live birth after 34 weeks of gestation    45/76(59.2)   42/74 (56.8) 1.0 (0.8, 1.4) 0.76 
     Ectopic pregnancy    1/76(1.3)   0/74(0.0) NA NA 
     Miscarriage*    28/76(36.8)  25/74(33.8) 1.1 (0.7, 1.7) 0.70 
     Stillbirth    0/76(0.0)   0/76(0.0) NA NA 
     Preterm birth (before 37 weeks 0 days of gestation    5/45(11.1)   8/48(16.7) 0.7 (0.3, 2.0) 0.54 
     Infant birth weight (g)        
          Median     3420.0   3300.0   
          Range     3005-3920   2690-3610   
Neonatal outcomes†     
     Infants discharged alive from hospital      46/46(100.0)   49/49(100.0)   
     Any congenital anomaly     1/46(2.2)   1/49(2.0) 0.9 (0.1, 13.4) 0.93 
Adverse events⨕     n/N (%)    n/N(%)   
     Maternal adverse events     52/76(68.4)  43/74(58.1)      1.2 (0.9, 1.5) 0.20 
     Serious adverse events     8/76(10.5)  6/74(8.1)  1.3 (0.5, 3.6) 0.62 
Incidence of anti-drug antibody formation     0/76(0.0)  NA NA NA 
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Figure 5.2 – Distribution of gestational age according to study group assignment. 
Placebo            rhG-CSF 
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Subgroup Analysis 
Findings of subgroup analysis are given in table 5.11. 
 
Maternal age at randomisation 
The live birth rate for maternal age under 35 years was 58.1% (36/62) in the rhG-
CSF group, compared with 66.7% (40/60) in the placebo group, giving a RR of 
0.9 (95% CI: 0.7 to 1.2; p=0.33). There was a smaller percentage of women under 
the age of 35 in the rhG-CSF group. The live birth rate for maternal age equal to 
or more than 35 years was 64.3% (9/14) in the rhG-CSF group, compared with 
57.1% (8/14) in the placebo group, giving a RR of 1.1 (95% CI: 0.6 to 2.1; p=0.71).  
Subgroup analysis based on maternal age at randomisation did not confirm any 
significant effects between rhG-CSF and placebo arms. 
 
Previous Miscarriages 
The live birth rate for women who had 3 previous miscarriages were 63.9% 
(23/36) in the rhG-CSF group, compared with 67.6% (23/34) in the placebo 
group, giving a RR of 0.9 (95% CI: 0.7 to 1.3; p=0.67). The live birth rate for 
women who had 4 previous miscarriages were 75% (12/16) in the rhG-CSF 
group, compared with 65% (13/20) in the placebo group, giving a RR of 1.3 (95% 
CI: 0.8 to 2.0; p=0.26). The live birth rate for women who had 5 previous 
miscarriages were 57.1% (4/7) in the rhG-CSF group, compared with 40% (4/10) 
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in the placebo group, giving a RR of 1.3 (95% CI: 0.5 to 3.6; p=0.58). The live 
birth rate for women who had more than 5 previous miscarriages were 35.3% 
(6/17) in the rhG-CSF group, compared with 80.0% (8/10) in the placebo group, 
giving a RR of 0.5 (95% CI: 0.2 to 1.0; p=0.06). 
Subgroup analysis based on previous number of miscarriages did not confirm 
any significant effects between rhG-CSF and placebo arms. 
 
Gestation at randomisation 
The live birth rate for women who were randomised at less than or equal to 4 
weeks of gestation was 58.3% (42/72) in the rhG-CSF group, compared with 
64.70% (44/68) in the placebo group, giving a RR of 0.9 (95% CI: 0.7 to 1.2; 
p=0.43). Live birth rate for those randomised above 4 weeks of gestation until 5 
weeks were 75.0%(3/4) in the rhG-CSF group, compared with 66.7% (4/6) in the 
placebo group, giving a RR of 1.1 (95% CI: 0.6 to 2.1; p=0.73). 
Subgroup analysis based on gestation at randomisation did not confirm any 
significant effects between rhG-CSF and placebo arms. 
 
Primary and Secondary Miscarriages 
The live birth rate for women had secondary miscarriages were 63.2% (24/38) in 
the rhG-CSF group, compared with 62.2% (23/37) in the placebo group, giving a 
RR of 1.01 (95% CI:0.71to 1.44; p=0.92). Live birth rate for those with primary 
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miscarriages were 55.3% (21/38) in the rhG-CSF group, compared with 67.6% 
(25/37) in the placebo group, giving a RR of 0.81(95% CI: 0.57 to 1.17; p=0.27). 
Subgroup analysis based on primary and secondary miscarriages did not 
confirm any significant effects between rhG-CSF and placebo arms. 
 
Previous late miscarriages 
The live birth rate for women had a previous late miscarriage was 53.8% (7/13) 
in the rhG-CSF group, compared with 60.0% (6/10) in the placebo group, giving 
a RR of 0.91 (95% CI: 0.43 to 1.80; p=0.76). Live birth rate for those without late 
miscarriage was 60.3% (38/63) in the rhG-CSF group, compared with 65.6% 
(42/64) in the placebo group, giving a RR of 0.91(95% CI: 0.70 to 1.20; p=0.53). 
Subgroup analysis based on previous late miscarriages did not confirm any 
significant effects between rhG-CSF and placebo arms. 
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Subgroup                                              rhG-CSF                  Placebo                   Relative risk                                P value 
                                                                 n/N(%)                   n/N(%)                    (95% CI) 
Age*     
< 35 years          36/62(58.1) 40/60(66.7) 0.9 (0.7, 1.2) 0.33 
≥ 35 years          9/14(64.3) 8/14(57.1)  1.1 (0.6, 2.1) 0.71 
     
Previous miscarriages     
3          23/36(63.9) 23/34(67.6) 0.9 (0.7, 1.3) 0.67 
4          12/16(75.0) 13/20(65.0) 1.3 (0.8, 2.0) 0.26 
5          4/7(57.1)               4/10(40.0) 1.3 (0.5, 3.6) 0.58 
>5          6/17(35.3)              8/10(80.0) 0.5 (0.2, 1.0) 0.06 
     
Gestation at treatment start     
≤4 weeks          42/72(58.3) 44/68(64.70 0.9 (0.7, 1.2) 0.43 
>4 weeks          3/4 (75.0)            4/6(66.7)                         1.1 (0.6, 2.1) 0.73 
     
Previous Live Birth     
Yes         24/38(63.2) 23/37(62.2) 1.01 (0.71, 1.44) 0.92 
No         21/38(55.3) 25/37(67.6) 0.81 (0.57, 1.17) 0.27 
     
Previous miscarriage after 12 
weeks 
    
Yes         7/13(53.8) 6/10(60) 0.91 (0.43, 1.8) 0.76 
No        38/63(60.3) 42/64(65.6) 0.91 (0.70, 1.20) 0.53 
 
Table 5.11 – Subgroup analysis by maternal age at randomisation 
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Adverse Events 
 
Adverse events are listed in table 5.12. 
 
The most common adverse event experienced was gastrointestinal disorder 
followed by nervous and musculoskeletal disorders. Gastrointestinal disorders 
were experienced by 43.4 %( 33/76) in the rhG-CSF compared to 32.4 %( 24/74) 
in the placebo group, giving a RR of 1.3(95% CI: 0.9 to 2.0; p=0.17). Nervous 
system disorders were experienced by 27.6 %( 21/76) in the rhG-CSF compared 
to 18.9% (14/74) in the placebo group, giving a RR of 1.5(95% CI: 0.8 to 
2.6;p=0.22). Musculoskeletal disorders were experienced by 26.3%( 20/76) in the 
rhG-CSF compared to 8.1%(6/74) in the placebo group, giving a RR of 3.2(95% 
CI: 1.4 to 7.5;p=0.01).There were 10.5 %( 8/76) serious adverse events in the rhG-
CSF group vs 8.1% (6/74) in the placebo group, giving a RR of 1.3(95% CI: 0.5 to 
3.6; p= 0.62). All SAEs in both treatment groups were considered to be likely 
unrelated. The occurrence of SAEs was broadly balanced in the 2 treatment 
groups, and no trend in their occurrence was obvious. The majority of SAEs 
reported during the study could be considered to be pregnancy related, and no 
SAE was considered to be related to study drug. The rhG-CSF group reported 
fewer AEs leading to discontinuation than the placebo group (2 women [2.6%] 
compared with 3 subjects [4.1%], respectively). Women in rhG-CSF group 
experienced more AEs related to study drug than the placebo treatment group. 
AEs that occurred during this study were generally mild or moderate in 
158 
 
severity and balanced in severity between the 2 treatment groups. The 
occurrence of AEs considered to be related to study therapy was also similar in 
the 2 treatment groups. No AEs of special interest were reported during this 
study. Among these, serious adverse events in the rhG-CSF group comprised of 
2 occurrences of gastrointestinal disorders, a   diagnosis of cholecystitis, a 
diagnosis of lower respiratory tract infection and 1 occurrence of severe 
headache, whereas serious adverse events in the placebo group comprised of a 
diagnosis of pneumonia and a diagnosis of endometritis.  
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Table 5.12 – Adverse events in RESPONSE study
  Adverse event                                                                                     rhG-CSF                                  Placebo                                Relative Risk                     P  value 
                                                                                                    n(n/N)                                      n(n/N)                                    (95% CI)                                                                 
Number of participants                                                                        76                                                74 
Blood and lymphatic system disorders 4 (5.3) 1(1.4)                              3.9 (0.4, 34.2)                          0.22 
Cardiac disorders 1(1.3) NA                                 NA 
Gastrointestinal disorders 33(43.4) 24(32.4)                          1.3 (0.9, 2.0)                           0.17 
General disorders  10(13.2) 13(17.6)                          0.7 (0.4, 1.6)                           0.44 
Hepatobiliary disorders 1(1.3)  NA                                  NA 
Immune system disorders 2(2.6)  NA                                  NA 
Infections and infestations 16(21.1)                                       10 (13.5)                      1.6 (0.8, 3.2)                           0.23 
Injury, poisoning and procedural complications 2(2.6)                                           3(4.1)                              0.6 (0.1, 3.7)                            0.63 
Significantly deranged serum parameters  8(10.5)                                         5(6.8)                              1.6 (0.5, 4.6)                            0.42 
Musculoskeletal and connective tissue disorders 20(26.3) 6(8.1)                             3.2 (1.4, 7.5)                            0.01 
Nervous system disorders 21(27.6) 14(18.9)                         1.5 (0.8, 2.6)                            0.22 
Pregnancy, puerperium and perinatal conditions 8(10.5) 4(5.4)                             2.0 (0.6, 6.1)                            0.25 
Psychiatric disorders 1(1.3) NA                                  NA 
Renal and urinary disorders 1(1.3) 1(1.4)                             1.0 (0.1, 15.5)                         0.99 
Reproductive system and breast disorders 19(25.0) 1(14.9)                           1.7 (0.9, 3.3)                           0.13 
Respiratory, thoracic and mediastinal disorders 4(5.3) 2(2.7)                             1.9 (0.4, 10.3)                         0.44 
Skin and subcutaneous tissue disorders 8(10.5) 2(2.7)                             3.9 (0.9, 17.8)                         0.08 
Vascular disorders 1(1.3) 1(1.4)                             1.0 (0.1, 15.2)                         0.98 
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Haematology Variables 
In the rhG-CSF group, a general trend was noted in shifts from normal values 
to higher individual WBC values and higher neutrophil counts, which shifted 
back to normal at 4 weeks post treatment. An additional trend was noted in 
shifts from baseline values in lymphocytes to low values on treatment.  
 
Figure 5.3 to figure 5.7 demonstrates the changes from baseline in haemoglobin, 
WBCs, neutrophils, and lymphocytes. While haemoglobin values over time 
were generally similar in both the active and placebo treatment groups, values 
in rhG-CSF groups were strikingly different from placebo across time points 
and served to demonstrate that the treatment was active in producing the 
intended biological effect. 
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Figure 5.3 – Mean change from baseline (+/- SD) in Haemoglobin 
Placebo            rhG-CSF 
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Figure 5.4 – Mean change from baseline (+/- SD) in White Blood Cells  
 
 
 
Placebo            rhG-CSF 
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Figure 5.5 – Mean change from baseline (+/- SD) in Neutrophils. 
 
Placebo            rhG-CSF 
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Figure 5.6 – Mean change from baseline (+/- SD) in Lymphocytes. 
  
Placebo            rhG-CSF 
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Figure 5.7 – Mean change from baseline (+/- SD) in Platelets.  
 
 
Placebo           rhG-CSF 
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Biochemistry Variables 
The values in the biochemistry variables for the 2 treatment groups were 
generally balanced at baseline.  
The treatment groups had similar alkaline phosphatase values at baseline, but 
following study treatment at the study Week-1 time point, the subjects in rhG-
CSF group had consistently higher mean alkaline phosphatase values compared 
with the placebo group at all time points while on treatment. At 4 weeks after 
study treatment, values for ALP returned to being again similar in the 2 
treatment groups.  
Mean alanine aminotransferase values were generally similar at baseline; on-
treatment values were modestly higher in rhG-CSF group at all on-treatment 
time points. Mean LDH was broadly comparable at baseline, but increased 
steeply at on-treatment time points in rhG-CSF group. By the 4 weeks post-
treatment visit, values across the 2 treatment groups were nearly the same for 
LDH.  
Mean values in gamma glutamyl-transferase were very slightly higher in the 
placebo treatment group at baseline but by on-treatment study Week 1 became 
higher in rhG-CSF group. The higher values in rhG-CSF group for GGT 
continued to be higher in the rhG-CSF group at all on-treatment time points, 
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and dropped at the 4 weeks post treatment time point to be slightly lower than 
gamma glutamyl-transferase values in the placebo group.  
Figure 5.8 to 5.12 graphically shows changes from baseline across study time 
points in alkaline phosphatase, ALT, AST, LDH, and GGT. 
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Figure 5.8 – Mean change from baseline (+/- SD) in Alkaline Phosphatase. 
 
 
 
Placebo            rhG-CSF 
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Figure 5.9 – Mean change from baseline (+/- SD) in Alanine Transaminase. 
 
 
 
Placebo            rhG-CSF 
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Figure 5.10 – Mean change from baseline (+/- SD) in Aspartate Amino Transferase. 
 
 
 
Placebo            rhG-CSF 
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Figure 5.11 – Mean change from baseline (+/- SD) in Lactate Dehydrogenase. 
  
Placebo            rhG-CSF 
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Figure 5.12 – Mean change from baseline (+/- SD) in Gamma –glutamyl Transferase.  
Placebo            rhG-CSF 
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Summary of Results 
Efficacy Profile 
Recombinant human granulocyte colony stimulating factor did not demonstrate 
efficacy in this study compared to placebo, in either the primary outcome 
measure of clinical pregnancy rate at Week 20 of gestation, or the secondary 
efficacy outcome measures. There were no statistically significant differences in 
clinical pregnancy rates and live birth rate between rhG-CSF and placebo. Three 
subjects in rhG-CSF group and 1 subject in the placebo group had an ectopic 
pregnancy. Interestingly, all women who maintained clinical pregnancy 
through Week 20 had outcomes of live birth (i.e, there were no late-term losses 
or stillbirths). All infants were discharged alive from the hospital.  
 
Safety profile 
 
Recombinant human granulocyte colony stimulating factor appeared to be 
generally safe and well tolerated in this study when administered as daily SC 
injections of 130 mcg for up to 9 weeks. The vast majority of reported TEAEs 
were of mild to moderate severity, and there were no statistically significant 
differences between the rhG-CSF and placebo groups in rates or types of AEs 
leading to discontinuation, AEs related to study drug, or SAEs. One Grade-4 
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event was reported in a rhG-CSF treated subject (ectopic pregnancy), but this 
was considered to be likely unrelated to study drug.  
 
Laboratory changes, including elevations in WBC and neutrophil counts, were 
transient and consistent with the known effects of rhG-CSF treatment. There 
were no clinically significant differences in vital sign parameters between the  
rhG-CSF and placebo groups. No evidence of immunogenicity was observed in 
this study.  
 
Headache was reported by 27.6% of s rhG-CSF subjects and by 13.5% of placebo 
subjects. Injection site pain was not reported by any in the rhG-CSF group but 
by 4.1% of placebo subjects. Vomiting was seen at a higher rate in rhG-CSF 
group (14.5%) compared to placebo subjects (6.8%).  There were no statistically 
significant differences in neonatal outcomes between rhG-CSF and placebo 
groups. All women who had a clinical pregnancy at 20 weeks of gestation 
progressed to live birth, and all infants were discharged alive from the hospital. 
Birth weights and 1- and 5-minute Apgar scores were comparable. There were 
only two major congenital anomalies, one urethral cyst in rhG-CSF group and 
one heart defect in the placebo group respectively.  
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CHAPTER 6 
  
DISCUSSION AND CONCLUSIONS OF  A RANDOMISED, DOUBLE 
BLIND, MULTICENTRE, PLACEBO-CONTROLLED STUDY TO 
EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF 
RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING 
FACTOR   IN PREGNANT WOMEN WITH A HISTORY OF 
UNEXPLAINED RECURRENT MISCARRIAGES 
 
Discussion 
 
Immune mediated mechanisms are thought to contribute to recurrent 
pregnancy losses. Wide ranges of treatment options aimed at modifying 
maternal immune response are used and the latest addition to this group of 
medication is G-CSF. 
 
 
This large multicentre, randomised, placebo-controlled trial investigated the 
efficacy and safety of recombinant human granulocyte colony stimulating factor 
in women with a history of unexplained recurrent miscarriages. The study 
showed that rhG-CSF therapy used throughout the first trimester of pregnancy 
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did not result in a significant increase in clinical pregnancies at 20 weeks or live 
births among women with a history of unexplained recurrent pregnancy losses.  
Participant flow within the study and the baseline characteristics were similar 
between the study groups. There were no statistically significant differences in 
the primary and secondary outcomes in the study. Out of the 340 women 
screened, 150 women were randomised in a 1:1 ratio and all women in the 
study were followed up as appropriate. Subgroup analysis based on maternal 
age at randomisation also did not show any differences between the two 
treatment arms.  
 
As anticipated, there were significant increases in both haematology and 
biochemistry parameters in the active treatment group. These changes returned 
to baseline values after discontinuation of the medications. The study did not 
show any significant increase in adverse events between the two groups. 
 
 
This study does not support the findings of the only previous randomised 
control study evaluating G-CSF in recurrent pregnancy losses73.  In this 
previous, smaller, single center study of 68 patients, Scarpellini et al., suggested 
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statistically significant improvement in live birth rates between the rhG-CSF 
group and in the placebo group (82.8% versus 48.5%).  
A systematic narrative review of previous studies suggested significant clinical 
effect of G-CSF in improving outcomes for women having assisted reproductive 
techniques and also for those who had G-CSF as a treatment option for 
recurrent miscarriages. Out of the 17 studies, 12 investigated efficacy of G-CSF 
in assisted conception techniques and five investigated the efficacy of G-CSF in 
recurrent miscarriages. 
 
12 studies within the ART population included three randomised controlled 
studies and nine observational studies. Three RCT conducted by Aleyasan et 
al., Davari-Tanha et al., and Eftekhar et al. confirmed benefits with G-
CSF168,170&171. The observational studies also suggested benefit. One RCT169 by 
Barad et al., and an observational study167 by Eftekhar et al., did not confirm 
any significant improvement in outcomes. Most of the above studies used G-
CSF regimen based on body weight dependant target dose. The active 
medication was administered as a single dose or multiple dose. The route of 
administration was subcutaneous or as an intrauterine infusion. An 
observational study by Zeyneloglu et al., used a dual administration 
technique178. 
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Five studies investigating the effect of G-CSF in women with recurrent 
miscarriage included one RCT and 4 observational studies. RCT by Scarpellini 
et al73 and 3 observational studies confirming benefit with G-CSF whereas the 
observational study based on population registry on SCNIR by Zeidler 
suggested no benefit with G-CSF181.  
 
However, all the above studies were of poor quality. 
 
Zhao et al. published a systematic review and meta-analysis investigating the 
effects of G-CSF in ART suggested improvement in all outcomes in ART, if G-
CSF was administered as a subcutaneous injection198. A small cohort study by 
Zeyneloglu et al., also suggested that dual administration, in form of 
subcutaneous and intrauterine infusion, of G-CSF significantly improved live 
birth rates178.  
 
The above studies both in the ART population and RM population had 
significant heterogeneity due to the variable patient population, indication for 
G-CSF, dose and routes of administration. Therefore, researchers called for 
larger well-designed studies.  
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RESPONSE study utilised the biological effect of G-CSF to rapidly increase the 
peripheral blood cell subsets, mainly the neutrophil population. This effect was 
hypothesised to result in changes consistent with supporting a state of 
maternal-fetal immune tolerance by temporary induction of toleragenic cell 
subsets and decreased percentages of pro-inflammatory and cytotoxic cell 
subsets.  
 
Rise in WBC subsets was confirmed by the observed changes in haematology 
parameters confirming biological effect of rhG-CSF, as anticipated. 
 
These biological effects, however, did not translate into any meaningful 
increase in clinical outcomes within this study. Therefore, it may be postulated 
that the clinical effects were overstated in previous studies. 
 
This study on efficacy of G-CSF in unexplained RM also had some limitations. 
First of all, the tests performed as part of screening did not include any specific 
immune tests to identify immune dysfunction as the reason for pregnancy 
losses. This was mainly because of lack of a universally accepted test(s) for 
immune dysfunction in reproductive immunology. However, addition of 
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immune testing specific to implantation G-CSF deficiency syndrome may have 
provided more information on both immune physiology and treatment 
outcomes. Herrler et al and Makrigiannakis et al in their studies investigating 
maternal fetal interactions suggested that killer immunoglobulin like receptor 
along with uterine NK cells had a major role in implantation and 
development199,200. These are controlled by activation and inhibition genes. Lack 
of suppression of inhibitory genes as suggested by Varla-Leftherioti et al can 
derange the implantation process201. Hiby et al suggested the same outcome if 
there was lack of activator genes202,203. Benefits of G-CSF administration for 
women lacking these genes were demonstrated by Wurfel et al and 
Santjohanser et al196,204 The concept of implantation specific G-CSF deficiency 
syndrome was introduced by these study groups.  
 
Secondly, this study did not routinely perform analysis for fetal karyotyping for 
women who suffered miscarriages. Wurfel et al suggested majority of 
miscarriage events in G-CSF group in their study were due to fetal 
chromosomal abnormalities130.  
 
The strengths of this study include the multicentre study design involving 21 
hospitals spread across the United Kingdom. After comprehensive 
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investigations 340 women with unexplained recurrent pregnancy losses were 
screened into this study. Thus, this study represents the largest placebo-
controlled randomised control study for rhG-CSF in women with unexplained 
recurrent pregnancy losses. Of these 150 women were randomised. These were 
women from different ethnic backgrounds. Participant compliance rate was 
high and all participants were followed up until completion of study endpoints, 
as appropriate. We initiated optimum dose of rhG-CSF as soon as the 
pregnancy was confirmed, which started as early as 7 days after ovulation.  
 
This study with strong methods provides further evidence for clinicians and 
researchers in reproductive medicine regarding efficacy and safety of rhG-CSF. 
They can translate this information to clinical practice to counsel women 
considering treatment for immune mediated miscarriages. This hopefully will 
prevent women from administering treatment options with no clinical effect 
which is expensive and which may add potential risk to the mother and/or the 
baby. 
 
This study has opened up a few research questions for the future. We are now 
considering a retrospective analysis of prospectively collected date for 
biomarker bloods to assess immune mechanisms.  There is also possibility of 
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developing an investigation panel for different up regulator and down 
regulator proteins or genes which control embryo  implantation process.  
 
Conclusions 
 
In conclusion, this trial showed no significant increase in clinical pregnancy or 
live births with the use of rhG-CSF in the first trimester of pregnancy among 
women with recurrent miscarriages. There was no increased risk of congenital 
anomalies among offspring of women treated with rhG-CSF, although the 
study was not powered for such rare outcomes.  
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Appendices 
 
Appendix 1. Protocol Amendments  
 
The RESPONSE protocol was effective on 05 Feb 2014. There were 2 
amendments that were prepared to document changes in the conduct of the 
study. 
  
Version 2 (first amendment to the effective protocol), dated 21 Mar 2014, made 
the following changes:  
 
 Clarified that participants were between 3 to 5 weeks of gestation at the 
time of randomisation and did not continue study drug administration 
beyond the Week 12 of gestation assessment. Therefore, the total 
duration of treatment was up to 9 weeks. Also clarified that visit timing 
was based on weeks of gestation.  
 
 Added language that the investigator had unrestricted and immediate 
access to unblind the participant’s treatment assignment by accessing the 
IWRS.  
 
 Removed “G-CSF levels” from the list of potentially unblinding 
laboratory values.  
 
 Removed Factor V Leiden mutation, prothrombin (Factor II) 20210 G>A 
mutation, prolactin, and anti-thyroid peroxidase antibodies from the list 
of screening tests.  
 
 Added a statement that daily home urine pregnancy tests had to start 5 
days before the start of the next period if the sixth day after ovulation 
had not yet occurred.  
 
 Removed the sentence “Subjects who are determined to be greater than 5 
weeks of gestation will not eligible for randomisation.”  
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Version 3 (second amendment to the effective protocol, dated 15 Aug 2014, 
made the following changes:  
 
 Revised the wording in the background section that states the estimated 
prevalence of recurrent loss of a clinical pregnancy, including a new 
reference to a 2012 American Society for Reproductive Medicine Practice 
Committee opinion.  
 Added a new exploratory pharmacodynamics outcome measure: 
changes in levels of circulating WBC subsets.  
 
 Clarified in the Immunogenicity section that participants who developed 
an ADA response and were pregnant were cared for by an appropriate 
specialist. 
 
 Added language to the section on Blinding and Minimisation of Bias to 
standardize the process for informing participants and their general 
practitioners of pre randomisation FBC results and requesting that 
routine booking blood tests during pregnancy not include an FBC.  
 
 Clarified the wording in inclusion criterion #2 used to define 
documented history of unexplained RPL.  
 
 Clarified wording of exclusion criterion #6f, current or past diagnosis of 
cervical incompetence 
 
  Added a statement to the Excluded Therapies section that aspirin use 
was not excluded  
 
 Increased the time window of the Week 20 of Gestation Visit from ±3 
days to ±1 week.  
 
 Revised the title of Section 5 to “Assessment of Efficacy and 
Pharmacodynamics”. Added Section 5.2, a Pharmaco-dynamic 
assessment that describes the set of exploratory research biomarkers that 
were examined to better understand the effects of pregnancy and rhG-
CSF on immune cells. Added confirmation that genetic testing was not 
performed on any samples.  
 
208 
 
209 
 
210 
 
211 
 
212 
 
213 
 
214 
 
215 
 
216 
 
217 
 
218 
 
219 
 
220 
 
221 
 
222 
 
223 
 
224 
 
225 
 
226 
 
 
227 
 
 
228 
 
229 
 
Appendix 8: Study Acknowledgements 
I wish to thank all the women who participated in this study; all the principal 
investigators for supervising recruitment and randomization at the study 
centres; all the RESPONSE research nurses who assisted in study visits and 
collection of data; study pharmacists; the data and safety monitoring 
committee; Premier research, clinical research organisation; The Miscarriage 
Association; and all those not otherwise mentioned above who have 
contributed to the RESPONSE study. 
 
